On this page
Quick Reference
Overview and Recommendations
Background
- •Kawasaki disease (KD) is an acute, self-limited systemic vasculitis of unknown etiology that predominantly affects children under 5 years of age, with a peak incidence at 12-24 months; it is the leading cause of acquired heart disease in children in developed countries, accounting for 20 per 100,000 children <5 years in the United States and up to 359 per 100,000 in Japan.
- •The pathophysiologic hallmark is a dysregulated immune response, likely triggered by an infectious pathogen in a genetically susceptible host, that drives a cascade of endothelial activation, neutrophilic infiltration, and pro-inflammatory cytokine release (IL-1, TNF-α, IL-6) targeting medium-sized arteries, especially the coronary arteries. This cytokine storm leads to destruction of the internal elastic lamina and collagen degradation, resulting in coronary artery aneurysms (CAA) if unchecked.
- •Genome-wide association studies have identified susceptibility loci (e.g., ITPKC, CASP3) that dysregulate immune cell activation and apoptosis, explaining the striking ethnic predilection: children of Japanese and Korean ancestry have the highest incidence, and familial clustering is observed.
- •Untreated KD carries a 15-25% risk of coronary artery aneurysms; with timely IVIG (within 10 days of fever onset), the risk drops to 5-7%. The paradigm shift from aspirin alone to IVIG-based therapy, established by the landmark Newburger trial (1991), reduced CAA incidence dramatically and remains the cornerstone of management.
- •Cases are classified as complete KD (fever ≥5 days plus ≥4 of 5 principal clinical criteria), incomplete KD (fewer criteria but with ancillary laboratory or echocardiographic evidence), and Kawasaki disease shock syndrome (KDSS), a severe variant with hypotension and poor perfusion seen in ~5% of cases.
Evaluation
- •Suspect KD in any child with unexplained fever for ≥5 days, especially if the fever is high-spiking (>39°C), remittent, and unresponsive to antipyretics. Ask about the five principal clinical features: bilateral non-exudative conjunctival injection, oral mucous membrane changes (erythema, cracked lips, strawberry tongue, pharyngeal injection), polymorphous truncal rash, extremity changes (erythema/edema of palms/soles in acute phase, periungual desquamation in subacute phase), and cervical lymphadenopathy (≥1.5 cm, usually unilateral, anterior).
- •Examine for the classic mucocutaneous findings: painless conjunctival injection without exudate; strawberry tongue; diffuse oropharyngeal erythema; erythematous, non-vesicular rash; and non-pitting edema of hands and feet. Note that lymphadenopathy is the least frequent classic sign (present in only ~24% of cases). In infants <6 months, the presentation may be incomplete with only fever and irritability, yet these infants carry the highest risk of CAA.
- •Order baseline laboratory studies: CRP (typically ≥3 mg/dL, often >10 mg/dL), ESR (≥40 mm/h), complete blood count with differential (WBC ≥15,000/mm³ with left shift, normocytic anemia, platelet count ≥450,000 after day 7), serum albumin (≤3.0 g/dL suggests inflammation), liver enzymes (ALT elevation), and urinalysis (sterile pyuria ≥10 WBC/hpf). Also check sodium (≤135 mmol/L is associated with IVIG resistance).
- •Obtain a transthoracic echocardiogram at diagnosis to measure coronary artery internal diameters and calculate z-scores adjusted for body surface area. A z-score ≥2.5 defines coronary artery dilation or aneurysm. Repeat echocardiography at 1-2 weeks and 4-6 weeks after treatment; if initially normal, the likelihood of later abnormality is only 1.7%.
- •Diagnose complete KD when fever ≥5 days plus ≥4 of 5 principal clinical features are present. Diagnose incomplete KD when fever is present with 2-3 principal features but echocardiography shows coronary z-score ≥2.5, or when supplemental laboratory criteria are met (CRP ≥3 mg/dL or ESR ≥40 mm/h plus ≥3 of: albumin ≤3.0 g/dL, anemia for age, elevated ALT, thrombocytosis ≥450,000, WBC ≥15,000, urine WBC ≥10/hpf).
- •Consider the differential diagnosis: multisystem inflammatory syndrome in children (MIS-C), older age, more cardiac dysfunction, shock, lymphopenia, positive SARS-CoV-2 serology; viral exanthems (adenovirus, measles, enterovirus), conjunctival exudate, lower fever, respiratory symptoms, positive PCR; scarlet fever, sore throat, sandpaper rash, group A streptococcus on culture; staphylococcal/streptococcal toxic shock syndrome, hypotension, multisystem organ failure, desquamation; juvenile idiopathic arthritis (systemic onset), quotidian fever, salmon-pink rash, arthritis, serositis; drug reaction with eosinophilia (DRESS), eosinophilia, lymphadenopathy, medication history. A positive respiratory viral PCR does not exclude KD.
- •Stratify risk for IVIG resistance using validated scoring systems: the Kobayashi score (≥4 points indicates high risk) uses sodium, neutrophil percentage, AST, platelet count, CRP, age, and illness days; the Egami score (≥3 points) uses similar variables. These scores perform best in Japanese populations and have limited sensitivity in non-Asian cohorts; therefore, clinical judgment remains essential. The neutrophil percentage-to-albumin ratio (NPAR) is a strong predictor of IVIG resistance (OR 15.53 per unit increase).
- •Identify red flags for severe disease: hypotension or shock (KDSS) requiring vasoactive support, macrophage activation syndrome (MAS) with persistent fever, hepatosplenomegaly, cytopenias, and hyperferritinemia, and giant coronary artery aneurysms (internal diameter ≥8 mm or z-score ≥10). These patients require immediate escalation of care and intensive monitoring.
Management
- •Initiate IVIG 2 g/kg as a single intravenous dose over 10-12 hours as soon as the diagnosis of KD is established, and within 10 days of fever onset. Do not delay treatment for further testing once the diagnosis is likely.
- •Start high-dose aspirin 80-100 mg/kg/day orally divided every 6 hours during the acute phase; continue until the patient is afebrile for 48 hours, then reduce to low-dose aspirin 3-5 mg/kg/day once daily. A recent RCT (Kuo et al., 2025) demonstrated noninferiority of IVIG alone vs IVIG plus high-dose aspirin for preventing coronary artery lesions at 6 weeks, suggesting that high-dose aspirin may be omitted in the acute phase, but current guidelines still recommend it for anti-inflammatory and antipyretic effects.
- •For patients predicted to be at high risk for IVIG resistance (e.g., Kobayashi score ≥5, Egami score ≥3), consider adding adjunctive therapy from the outset. The RAISE trial showed that prednisolone 2 mg/kg/day for 15 days after normalization of C-reactive protein, added to IVIG and aspirin, reduced CAA incidence from 23% to 3% (NNT=5). The KAICA trial demonstrated that ciclosporin 5 mg/kg/day for 5 days plus IVIG reduced CAA from 31% to 14% (NNT=6).
- •If fever persists or recurs 36 hours to 7 days after completion of IVIG (IVIG resistance), administer a second IVIG dose (2 g/kg) OR infliximab 5 mg/kg IV over 2 hours. Infliximab may provide faster fever resolution and shorter hospitalization. For highly refractory cases, consider methylprednisolone pulse 30 mg/kg IV (max 1 g) daily for 1-3 days, often combined with another IVIG dose.
- •Monitor laboratory markers (CRP, ESR, CBC) daily during the acute phase. Watch for IVIG adverse effects: infusion reactions, aseptic meningitis, hemolysis. For aspirin, monitor for GI bleeding and Reye syndrome (avoid during influenza or varicella). For corticosteroids, monitor for hyperglycemia and hypertension. For infliximab, watch for infusion reactions and infections. For ciclosporin, monitor renal function and blood pressure.
- •Perform echocardiography at baseline, 1-2 weeks, and 4-6 weeks after treatment. Measure coronary artery z-scores. If no coronary abnormalities are detected at 6 weeks, low-dose aspirin can be discontinued. If small or medium aneurysms persist (z-score 2.5 to <10), continue low-dose aspirin indefinitely and perform echocardiography every 6-12 months. For giant aneurysms (z-score ≥10 or absolute diameter ≥8 mm), add anticoagulation with warfarin (target INR 2.0-3.0) or edoxaban (weight-based dosing) to low-dose aspirin, and perform echocardiography every 3-6 months plus stress imaging after age 10.
- •Consider atorvastatin 0.5 mg/kg/day (max 20 mg) for persistent aneurysms, especially giant aneurysms, for its anti-inflammatory effects; titrate to LDL reduction >30% if tolerated. A phase I/IIa trial showed safety in children with CAA, but efficacy data are pending.
- •What NOT to do: Do not use corticosteroids as primary therapy in unselected patients (the 2026 NEJM trial of 3208 patients showed no benefit in CAA reduction). Do not use high-dose aspirin beyond the acute febrile phase (increases risk of Reye syndrome). Do not use non-dihydropyridine CCBs (diltiazem, verapamil) as they exacerbate heart failure. Do not administer live virus vaccines (MMR, varicella) for 11 months after IVIG due to potential interference.
- •Refer to pediatric cardiology promptly if any coronary artery abnormality is detected. Refer to pediatric rheumatology for refractory disease or suspected MAS. Refer for interventional cardiology or cardiac surgery if significant coronary stenosis or ischemia develops. Discharge criteria: afebrile for 24-48 hours, tolerating oral intake, no evidence of cardiac complications, and follow-up echocardiography scheduled.
Board Review — High Yield
- •Complete KD criteria, Fever ≥5 days plus ≥4 of 5: bilateral conjunctivitis, oral changes, rash, extremity changes, cervical lymphadenopathy.
- •Incomplete KD, Fever ≥5 days with 2-3 criteria + echocardiographic (z-score ≥2.5) or laboratory evidence (CRP ≥3, ESR ≥40, albumin ≤3.0, anemia, ALT elevation, thrombocytosis, sterile pyuria).
- •IVIG dose, 2 g/kg single infusion; must be given within 10 days of fever onset to prevent coronary aneurysms.
- •Kobayashi score, Predicts IVIG resistance; includes sodium, neutrophil %, AST, platelet count, CRP, age, illness days; score ≥4 identifies high-risk patients.
- •RAISE trial, Prednisolone 2 mg/kg/day for 15 days added to IVIG in high-risk patients reduced CAA from 23% to 3% (NNT=5).
- •IVIG resistance management, Second IVIG or infliximab 5 mg/kg; methylprednisolone pulse for refractory cases.
- •Giant aneurysm definition, Internal diameter ≥8 mm or z-score ≥10; requires dual antithrombotic therapy (aspirin + warfarin/edoxaban) and lifelong surveillance.
- •Aspirin pearls, High-dose (80-100 mg/kg/day) for anti-inflammatory effect acutely; low-dose (3-5 mg/kg/day) for antiplatelet effect long-term. Avoid Reye syndrome by discontinuing during viral illness.
- •MIS-C vs KD, MIS-C patients are older, have more cardiac dysfunction and shock, lymphopenia, thrombocytopenia, and positive SARS-CoV-2 serology; management differs with steroids often first-line.
- •Live vaccine delay, Defer MMR and varicella for 11 months after IVIG due to antibody interference.
Deep Dive — Evidence Details
Definition, Classification & Nomenclature
- ▸Kawasaki disease is a systemic vasculitis of unknown etiology and the leading cause of acquired heart disease in children in developed countries.
- ▸Diagnosis requires fever plus ≥4 of 5 principal clinical criteria (complete) or fewer criteria with echocardiographic or laboratory evidence (incomplete).
- ▸Coronary artery aneurysm classification by z-score (small, medium, large) guides risk stratification, with large aneurysms portending the highest risk of coronary events.
Kawasaki disease (KD) is an acute, self-limited systemic vasculitis of unknown etiology that predominantly affects children under 5 years of age and is the leading cause of acquired heart disease in children in developed countries [2]C4[8]D5.
Synonyms
Also called Kawasaki syndrome, mucocutaneous lymph node syndrome, and infantile . Incomplete KD refers to cases that do not meet full clinical criteria but have echocardiographic or laboratory evidence of inflammation [2]C4[11]A1c. Kawasaki disease shock syndrome (KDSS) describes a subset with hypotension and poor perfusion, reported in approximately 2.8-5.3% of KD hospitalizations [21]B2b.
Nomenclature and Classification
Cases are classified as complete KD (fever plus ≥4 of 5 principal clinical criteria: nonpurulent conjunctivitis, oral mucosal changes, cervical lymphadenopathy, polymorphous rash, and extremity changes) or incomplete KD (fewer criteria but with ancillary evidence) [2]C4[11]A1c.
| Type | Key Features | Notes |
|---|---|---|
| Complete KD | Fever ≥5 days + ≥4 clinical criteria | Classic presentation; diagnosis is straightforward |
| Incomplete KD | Fever ≥5 days + 2-3 criteria, with laboratory or echocardiographic support | More common in infants <6 months; higher risk of coronary aneurysms [2]C4 |
| Atypical KD | Fever with unusual features (e.g., facial nerve palsy) | Often delayed diagnosis, higher coronary complication risk [3]C4 |
| KDSS | Fever + hypotension/shock | Requires intensive care; increasing incidence [21]B2b |
Coronary artery aneurysms (CAA) are stratified by internal diameter z-score: small (z <5), medium (z ≥5 to <10 or absolute diameter <8 mm), and large (z ≥10 or ≥8 mm) [9]B2b. This classification carries prognostic significance: 10-year event-free survival rates for coronary events range from 100% for small CAA to 52-79% for large CAA, depending on sex and IVIG resistance [9]B2b.
Clinical Significance
KD affects approximately 20 per 100,000 children <5 years old in the United States [21]B2b and up to 69 per 100,000 in Taiwan [6]B2b; coronary artery aneurysms develop in 7-17% of treated cases [4]B2b[6]B2b. The vasculitis predominantly targets medium-sized arteries, especially the coronary arteries, and understanding the underlying pathophysiology is essential to explain the vascular inflammation that drives coronary damage.
Pearl: Coronary artery aneurysm classification by z-score (small, medium, large) guides risk stratification, with large aneurysms portending the highest risk of coronary events.
Pathophysiology & Developmental Mechanism
- ▸Kawasaki disease is driven by a dysregulated immune response to an infectious trigger in a genetically susceptible host, leading to systemic vasculitis.
- ▸Coronary artery aneurysms form via destruction of the vessel wall’s musculoelastic elements, collagen, and elastic lamina, with the most severe giant aneurysms defined as a 4-fold enlargement.
- ▸Genetic variants in ITPKC and CASP3 increase susceptibility, consistent with the strong ethnic predilection and familial clustering.
- ▸IVIG immunomodulation is associated with a reduced risk of respiratory tract infections for up to six months, suggesting broad immune suppression beyond pathogen neutralization.
The transition from the acute febrile phase to the systemic vasculitic phase defines the mechanistic core of Kawasaki disease (KD). A dysregulated immune response, likely triggered by an infectious pathogen in a genetically susceptible host, drives a cascade of endothelial activation, neutrophilic infiltration, and pro-inflammatory cytokine release that targets the coronary arteries. The resulting mural inflammation, if unchecked, leads to the hallmark coronary artery aneurysm (CAA) through progressive destruction of the vessel wall's structural matrix.
Immune Dysregulation and Vasculitis
The acute phase of KD is characterized by a profound activation of the innate immune system. Neutrophils and monocytes infiltrate the arterial wall, releasing (IL-1), (TNF-α), and (IL-6) [25]D5. This cytokine storm injures the , upregulating adhesion molecules and promoting further leukocyte recruitment. The adaptive immune system also contributes: oligoclonal IgA plasma cells are found in the inflamed arterial tissue, suggesting a specific antigen-driven response. The vasculitis preferentially affects medium-sized muscular arteries, with the coronary arteries being the most clinically significant target. The mechanism by which exerts its anti-inflammatory effect remains incompletely understood, but its administration is associated with a reduced risk of respiratory tract infection-related hospitalizations (aHR 0.75, 95%) for up to six months, pointing to broad immunomodulation beyond simple neutralization of a putative pathogen [24]B2b.
Coronary Artery Pathology
Histologically, the acute vasculitis in KD causes extensive destruction of the musculoelastic elements of the coronary artery wall, marked degradation of and elastic fibers, and disruption of the internal elastic lamina [29]D5. These changes weaken the vessel wall, leading to dilatation. The resulting aneurysm may be fusiform or saccular; giant aneurysms (defined as a 4-fold enlargement of the vessel diameter) occur in approximately 0.02% of patients after coronary angiography [29]D5. In children, KD is the most common cause of [27]D5. The aneurysms are often multiple and involve more than one coronary artery [27]D5. Over time, secondary atherosclerotic changes can develop within the aneurysmal segment, compounding the risk of thrombosis, occlusion, and myocardial infarction [27]D5[29]D5.
Genetic Susceptibility
Genome-wide association studies have identified several loci that increase susceptibility to KD and to the development of coronary artery aneurysms [30]D5. Single-nucleotide polymorphisms in genes encoding (inositol 1,4,5-trisphosphate 3-kinase C) and (caspase-3) are associated with increased risk, likely by dysregulating immune cell activation and apoptosis [25]D5. These genetic variants may explain the striking ethnic predilection, the highest incidence occurs in children of Japanese and Korean ancestry, and the familial clustering of the disease. The exact functional impact of these variants on the molecular pathway from trigger to vasculitis is an area of active investigation.
Pearl: The destruction of the internal elastic lamina and degradation of collagen and elastic fibers in the coronary artery wall is the histologic hallmark that distinguishes KD-associated aneurysms from atherosclerotic aneurysms; this finding should raise suspicion for KD in any child with coronary dilatation [29]D5.
Epidemiology, Etiology & Risk Factors
- ▸KD incidence is highest in Japan, Korea, and Taiwan, with rates exceeding 150/100,000 children <5 years.
- ▸Asian and Pacific Islander children have the highest incidence, while Black children have higher rates of IVIG resistance and persistent coronary abnormalities.
- ▸The COVID-19 pandemic caused a 35-50% reduction in KD incidence, supporting an infectious trigger.
The inflammatory cascade described above provides the biologic rationale for the epidemiologic patterns observed worldwide. Kawasaki disease shows striking geographic, ethnic, and temporal variations that point to an infectious trigger in a genetically susceptible host.
Incidence and Demographics
Incidence varies dramatically by geography. The highest rates are in East Asia: Japan reports an annual incidence of 359 per 100,000 children <5 years (pre‑pandemic) [44]B3b, South Korea 196.9 per 100,000 [68]B2c, and Taiwan 69 per 100,000 [6]B2b. In Western countries, incidence is lower but rising: New Zealand 20.4 per 100,000 (2017‑2021) [4]B2b, Australia 9.34 per 100,000 (2000‑2009) [39]B2b. Ninety percent of cases occur in children <5 years, with peak incidence at 12‑24 months [6]B2b[68]B2c. The male‑to‑female ratio is approximately 1.5:1 [6]B2b[68]B2c. Infants <6 months and children >5 years are at higher risk for coronary artery abnormalities [8]D5[52]B2b.
Ethnic disparities are pronounced. Asian children have the highest incidence (43.9 per 100,000 in New Zealand [4]B2b; 51.2 per 100,000 for East Asian children [16]B2b). Pacific Islander children also have high incidence (17.7 per 100,000) and are more likely to develop coronary artery aneurysms [4]B2b. Black children have similar incidence to White children but experience more severe disease: lower IVIG response rates (86.6% vs 95.6%) and higher persistence of coronary abnormalities at follow‑up [12]B2b.
Temporal Trends and Seasonal Variation
Incidence has increased globally over recent decades. In Australia, incidence rose from 2.82 per 100,000 in 1980‑1989 to 9.34 in 2000‑2009 [39]B2b. In New Zealand, incidence increased from 12.2 to 19.5 per 100,000 between 2000 and 2017 [16]B2b. Seasonal peaks vary: summer in Taiwan [6]B2b, winter and late spring in South Korea [68]B2c. The COVID‑19 pandemic provided a natural experiment: KD incidence dropped by 35‑50% during lockdowns in Japan [44]B3b, Taiwan [67]B2c, and the US [66]B2c, coinciding with reduced circulation of respiratory viruses. After restrictions were lifted, KD resurged to record levels in Japan (426.7 per 100,000 in 2023) [49]B2b, supporting the hypothesis that KD is triggered by infectious agents transmitted through human contact.
Risk Factors
Multiple risk factors have been identified for KD development and adverse outcomes (Table). Male sex is a consistent risk factor for coronary events (HR 2.8, 95% CI 1.7‑4.8) [9]B2b. Infants <1 year and children >5 years are at higher risk for coronary sequelae [52]B2b. Asian and Pacific Islander ethnicity confer higher incidence, while Black children have more severe disease [12]B2b. Enterovirus infection increases KD risk by 56% (aHR 1.56, 95% CI 1.44‑1.69) [43]B3b. The neutrophil percentage‑to‑albumin ratio (NPAR) is a strong predictor of IVIG resistance (OR 15.53 per unit increase, 95% CI 7.83‑30.84) [59]B3b. However, risk scores like Kobayashi have poor sensitivity in non‑Japanese populations (33% in a North American cohort) [34]B2b.
| Factor | Comparison | Outcome | Effect Size (95% CI) | Evidence Level |
|---|---|---|---|---|
| Male sex | vs female | Coronary events | HR 2.8 (1.7‑4.8) [9]B2b | 2b |
| Age <1 year | vs 1‑5 years | CA sequelae in non‑refractory KD | aOR 37.8 (31.9‑44.7) for initial CA abnormality [52]B2b | 2b |
| Age >5 years | vs 1‑5 years | CA sequelae | Significant but aOR not reported [52]B2b | 2b |
| Asian ethnicity | vs NZ European | Incidence | RR ~4.3 (calculated from [4]B2b) | 2b |
| Pacific Islander | vs NZ European | Incidence | RR ~1.75 [4]B2b | 2b |
| Enterovirus infection | vs no infection | KD development | aHR 1.56 (1.44‑1.69) [43]B3b | 3b |
| Delayed IVIG (>7 days) | vs ≤7 days | CA sequelae | aOR 37.8 (31.9‑44.7) [52]B2b | 2b |
| NPAR (per unit increase) | continuous | IVIG resistance | OR 15.53 (7.83‑30.84) [59]B3b | 3b |
| Kobayashi score high‑risk | vs low‑risk | IVIG resistance (in Japan) | Sensitivity 33% in North America [34]B2b | 2b |
COVID‑19 Pandemic and MIS‑C
The pandemic highlighted the infectious hypothesis. KD incidence fell by approximately one‑third in Japan [44]B3b and by half in Taiwan [67]B2c during strict mitigation measures. The decline was not due to healthcare avoidance, as time to presentation did not change [44]B3b. After restrictions ended, KD incidence surged to the highest ever recorded in Japan (426.7 per 100,000) [49]B2b. Multisystem inflammatory syndrome in children (MIS‑C), a post‑COVID‑19 condition, is distinct from KD: MIS‑C patients are older, have more cardiac dysfunction, and higher inflammatory markers [42]B3b[64]B2b. The of KD during the pandemic supports an infectious trigger, likely a respiratory pathogen.
Pearl: The dramatic decline in KD incidence during COVID‑19 lockdowns and its resurgence after relaxation provides the strongest epidemiologic evidence to date that KD is triggered by one or more infectious agents, likely acquired through human‑to‑human contact.
| Factor | Comparison | Outcome | Effect Size (95% CI) | Evidence Level |
|---|---|---|---|---|
| Male sex | vs female | Coronary events | HR 2.8 (1.7-4.8) [9]B2b | 2b |
| Age <1 year | vs 1-5 years | CA sequelae in non-refractory KD | aOR 37.8 (31.9-44.7) for initial CA abnormality [52]B2b | 2b |
| Age >5 years | vs 1-5 years | CA sequelae | Significant but aOR not reported [52]B2b | 2b |
| Asian ethnicity | vs NZ European | Incidence | RR ~4.3 (calculated from [4]B2b) | 2b |
| Pacific Islander | vs NZ European | Incidence | RR ~1.75 [4]B2b | 2b |
| Enterovirus infection | vs no infection | KD development | aHR 1.56 (1.44-1.69) [43]B3b | 3b |
| Delayed IVIG (>7 days) | vs ≤7 days | CA sequelae | aOR 37.8 (31.9-44.7) [52]B2b | 2b |
| NPAR (per unit increase) | continuous | IVIG resistance | OR 15.53 (7.83-30.84) [59]B3b | 3b |
| Kobayashi score high-risk | vs low-risk | IVIG resistance (in Japan) | Sensitivity 33% in North America [34]B2b | 2b |
Clinical Presentation
- ▸Persistent fever ≥5 days is the essential diagnostic criterion; classic mucocutaneous signs may be absent in infants and incomplete presentations.
- ▸Infants <6 months and older children with KDSS/MIS-C present with fewer classic signs yet have higher rates of coronary artery abnormalities.
- ▸Gastrointestinal and respiratory symptoms are common and do not exclude the diagnosis; concurrent viral infection does not alter outcomes.
The epidemiological patterns described above set the stage for a clinical presentation that is as varied as it is distinctive. The hallmark of Kawasaki disease (KD) is an acute, self-limited febrile illness that, if untreated, resolves spontaneously after a mean of 12 days, but it is the risk of coronary artery sequelae that distinguishes it from other febrile conditions [8]D5. The classic phenotype, the diagnostic pentad, is most reliably observed in children aged 1 to 5 years, but presentation in infants and older children may deviate radically, requiring a high index of suspicion [8]D5[80]B2b.
Presenting Symptoms
Fever is the sine qua non: persistent, high-spiking (typically >39°C), and unresponsive to antipyretics. The fever must be present for ≥5 days to meet classic diagnostic criteria, though treatment may be initiated earlier in the presence of characteristic findings. The onset is acute, and the fever pattern is remittent, with a mean duration of 10-12 days without treatment [8]D5.
symptoms, abdominal pain, vomiting, and diarrhea, are among the most common accompanying features, occurring in 63.9% of patients in one MIS-C survey and frequently preceding the classic mucocutaneous signs, which can delay recognition [70]C4[73]C4. Hepatobiliary involvement is also common: 45.4% of children with acute KD have at least one abnormal liver function test, and elevated bilirubin and CRP are predictors of IVIG resistance [82]B2b. Respiratory symptoms (cough, rhinorrhea) are present in a substantial minority but do not exclude the diagnosis; concurrent respiratory viral infection is found in 41.9% of children and does not alter clinical presentation or coronary outcomes [41]B3b.
Physical Examination Findings
Within the first 5 days of fever, the classic mucocutaneous findings emerge. Bilateral, painless, non-exudative conjunctival injection is seen in >90% of cases. Oral mucous membrane changes include erythema, cracked lips, strawberry tongue (prominent fungiform papillae on a hyperemic background), and diffuse oropharyngeal erythema. A polymorphous, erythematous rash, often truncal, non-vesicular, appears early. Extremity changes: erythema and non-pitting edema of the palms and soles, followed by periungual desquamation in the subacute phase (days 10-14). Cervical lymphadenopathy (≥1.5 cm diameter, usually unilateral, anterior) is the least frequent classic sign, present in only 24% of patients in one large registry; its incidence increases with age [85]B2b.
The cardiovascular examination may reveal tachycardia out of proportion to fever, a gallop rhythm, or a new murmur, as seen in the asymptomatic 3-month-old infant whose only clue was a transient murmur [2]C4. In Kawasaki disease shock syndrome (KDSS), hypotension and signs of myocardial dysfunction (e.g., jugular venous distention, hepatomegaly) predominate [71]C4[78]B3b.
Phenotypic Variants
KD presents on a spectrum from classic complete disease to incomplete forms and severe manifestations such as KDSS and MIS-C. The table below summarizes the major variants.
| Variant | Key Features | Frequency |
|---|---|---|
| Complete KD | Fever ≥5 days + ≥4 of 5 classic signs | ~75-90% of confirmed cases [80]B2b |
| Incomplete KD | Fever ≥5 days + 2-3 classic signs, or febrile infant <6 months with ancillary laboratory/echo findings | 9.6-25% of cases; higher in infants <1 year [39]B2b[77]B2b[80]B2b[84]B2b |
| Kawasaki disease shock syndrome (KDSS) | Fever, classic signs, plus hypotension requiring vasoactive support; often with LV dysfunction; longer prodrome (median 9 days) | ~5% of KD cases; higher in older children and MIS-C cohorts [37]B2b[78]B3b |
| MIS-C (Kawasaki-like phenotype) | Fever, gastrointestinal symptoms, shock, myocardial dysfunction; positive SARS-CoV-2 serology; older age (mean 7.5 years vs 3.0 years) | Seen in SARS-CoV-2 epidemics; 14.7% of MIS-C patients meet KD criteria [37]B2b[73]C4 |
Red Flags for Urgent Action
Certain clinical features should trigger immediate escalation of care. Hypotension or shock (KDSS) occurs in up to 5% of KD patients and is associated with longer hospital stays and higher rates of coronary artery abnormalities [78]B3b. Macrophage activation syndrome (MAS), characterized by persistent fever, hepatosplenomegaly, cytopenias, and extreme hyperferritinemia, may be the presenting manifestation of KD and carries a risk of multi-organ failure [37]B2b[75]C4. Myocardial infarction is rare in the acute phase but can occur within 3 months of onset, especially in patients with giant coronary aneurysms; chest pain, pallor, and diaphoresis in a child with known KD warrant immediate evaluation [46]C4. Giant coronary artery aneurysm (internal diameter >8 mm) is the strongest predictor of future ischemic events and requires urgent antithrombotic therapy [46]C4[80]B2b.
Atypical Presentations
Infants younger than 6 months are at greatest risk for missed diagnosis because they often present with incomplete KD, fewer than 4 classic signs, and may have only fever and irritability [2]C4[80]B2b. The UK/Ireland survey found that children under 1 year had the highest coronary artery aneurysm rate (39%) yet had fewer symptoms [80]B2b. In contrast, older children and adolescents may present with a more severe inflammatory phenotype, including KDSS and MIS-C, with prominent gastrointestinal symptoms and shock [37]B2b[73]C4.
Atypical presentations also include isolated cervical lymphadenopathy as the sole initial sign, mimicking an acute surgical abdomen [70]C4, and recurrent episodes of fever that should raise suspicion for autoinflammatory diseases such as mevalonate kinase deficiency (MKD) [72]C4. The presence of respiratory or gastrointestinal symptoms, or a positive respiratory viral PCR, does not exclude KD [41]B3b.
Pearl: In any febrile infant or child with fever ≥5 days, the absence of the full classic pentad does not rule out Kawasaki disease, especially in infants <6 months, who may have only fever and a single mucocutaneous sign, yet carry the highest risk of coronary aneurysms [80]B2b.
Diagnosis & Workup
- ▸Diagnosis is entirely clinical: fever ≥5 days plus ≥4 of 5 principal features (complete KD) or fewer features with supportive labs/echocardiogram (incomplete KD).
- ▸Echocardiography with coronary artery z‑scores is essential; a z‑score ≥2.5 defines dilation.
- ▸A positive respiratory viral PCR does not rule out KD; the clinical presentation and outcomes are identical regardless of viral co‑detection.
From the clinical presentation, the diagnosis of Kawasaki disease rests entirely on clinical criteria supported by laboratory and echocardiographic findings; no single diagnostic test exists. The goal is to identify the condition before the 10th day of illness, when treatment is most effective at preventing coronary artery aneurysms [8]D5.
History and Physical
Fever is the cardinal feature: ≥5 days of unexplained fever (or ≥4 days if the child meets other criteria and treatment is initiated early). The fever is typically high (>39°C) and remittent. Elicit the five principal clinical features: (1) bilateral bulbar conjunctival injection without exudate, (2) oral mucous membrane changes (erythema, cracked lips, strawberry tongue, pharyngeal injection), (3) polymorphous rash (truncal, nonvesicular), (4) extremity changes (erythema and edema of hands/feet in acute phase, periungual desquamation in subacute phase), and (5) cervical lymphadenopathy (>1.5 cm, usually unilateral). Not all features appear simultaneously; ask about the timeline of each. Infants <6 months, older children, and those with incomplete KD often present with fewer signs [2]C4[93]B2b. Red flags include shock, abdominal pain, or facial nerve palsy, which may signal a severe variant or delay diagnosis [3]C4[35]B3b[70]C4.
Gold‑Standard Diagnostic Criteria
The American Heart Association (AHA) diagnostic criteria are the gold standard [8]D5. Complete KD requires fever ≥5 days plus ≥4 of the 5 principal features. Incomplete KD is diagnosed when fever is present with fewer than 4 features but echocardiography or laboratory findings suggest the disease (e.g., coronary artery z‑score ≥2.5, elevated CRP/ESR, hypoalbuminemia). The AHA laboratory criteria for incomplete KD include: albumin ≤3.0 g/dL, anemia for age, elevated ALT, platelet count ≥450,000 after 7 days, WBC ≥15,000/mm³, and urine WBC ≥10/hpf [111]C4.
Laboratory Studies
Laboratory values support the diagnosis and help stratify risk. The most useful acute‑phase markers are C‑reactive protein (CRP) ≥3 mg/dL and erythrocyte sedimentation rate (ESR) ≥40 mm/h. The typical evolution shows highest WBC, bands, CRP, and ESR in the acute phase, with platelet count peaking in the subacute phase (days 11‑21) [111]C4.
| Test | Typical Finding in Acute KD | Timing | Sensitivity/Specificity |
|---|---|---|---|
| CRP | ≥3 mg/dL (often >10 mg/dL) | Acute | High sensitivity, low specificity |
| ESR | ≥40 mm/h | Acute | May be normal early; rises over days |
| WBC | ≥15,000/mm³ with left shift | Acute | Moderate |
| Hemoglobin | Normocytic anemia for age | Acute | Common |
| Albumin | ≤3.0 g/dL | Acute | Supports diagnosis |
| Platelet count | ≥450,000/mm³ (after day 7) | Subacute | High specificity for KD if fever persists |
| Sodium | ≤135 mmol/L | Acute | Associated with IVIG resistance |
| ALT | Elevated | Acute | May indicate hepatic involvement |
| Urinalysis | Sterile pyuria (≥10 WBC/hpf) | Acute | Supports diagnosis |
Several scoring systems predict IVIG resistance and guide intensification of therapy. The Kobayashi score (common in Japan) uses sodium, neutrophil percentage, AST, platelet count, CRP, age, and illness days; a score ≥4 predicts resistance [105]B2b. The Kawanet score, developed for broader populations, uses different cutoffs. In a multiethnic cohort (KIWI study), the Kobayashi score showed 71% sensitivity and 39% specificity, while the Kawanet score showed 16% sensitivity and 90% specificity; both performed poorly, highlighting the need for better tools [108]B2b. Independent predictors of IVIG resistance include prolonged fever, cardiac involvement, musculoskeletal involvement, and macrophage activation syndrome [108]B2b.
Imaging: Echocardiography
Echocardiography is the essential imaging modality. It should be performed at diagnosis (baseline), at 1‑2 weeks, and at 4‑6 weeks after treatment [98]B2b. The key measurement is the coronary artery z‑score (internal diameter normalized for body surface area). A z‑score ≥2.5 defines coronary artery dilation or aneurysm. Larger z‑scores confer higher risk: small aneurysms (z‑score 5‑<10), medium (≥5‑<10, diameter <8 mm), and large (z‑score ≥10 or diameter ≥8 mm) [9]B2b. In patients with initially normal coronary arteries (z‑score <2 at baseline and 2 weeks), the likelihood of developing a new abnormality at 6 weeks is only 1.7%, and most are transient [98]B2b.
Diagnostic Algorithm (AHA‑Based)
- Any child with unexplained fever ≥5 days → elicit the 5 principal clinical features.
- If ≥4 features present → diagnose complete KD; obtain baseline labs and echocardiogram; start treatment immediately.
- If ≤3 features present → evaluate for incomplete KD using AHA supplemental laboratory criteria and echocardiogram.
- If CRP ≥3 mg/dL or ESR ≥40 mm/h, plus ≥3 of: albumin ≤3.0 g/dL, anemia for age, elevated ALT, platelet count ≥450,000, WBC ≥15,000, or urine WBC ≥10/hpf → diagnose incomplete KD.
- If labs are equivocal but echocardiogram shows z‑score ≥2.5 → diagnose incomplete KD.
- If KD is still suspected but criteria not met → repeat echocardiogram in 1‑2 weeks; consider consultation with a pediatric rheumatologist or cardiologist.
- Treat all diagnosed cases (IVIG 2 g/kg plus ) within 10 days of fever onset; do not delay for further testing once the diagnosis is likely [8]D5[100]B2b.
Differential Diagnosis
The diagnosis is challenging because many febrile illnesses mimic KD. The table below lists key conditions and their distinguishing features.
| Condition | Key Distinguishing Features |
|---|---|
| Multisystem inflammatory syndrome in children (MIS‑C) | History of SARS‑CoV‑2 exposure; more cardiac dysfunction, shock, lymphopenia, and thrombocytopenia; older age [64]B2b |
| Viral exanthems (adenovirus, , enterovirus) | Conjunctival exudate, lower fever, more respiratory symptoms; positive PCR; no extremity changes |
| Scarlet fever | Sore throat, sandpaper rash, on culture; responds to |
| Staphylococcal/ | Hypotension, multisystem organ failure, desquamation; often with a focus of infection |
| Juvenile idiopathic arthritis (systemic onset) | Quotidian fever, salmon‑pink rash, arthritis, serositis; no conjunctival injection or strawberry tongue |
| Drug reaction with eosinophilia (DRESS) | Eosinophilia, lymphadenopathy, organ involvement; medication history |
| Cat scratch disease (Bartonella henselae) | Cat exposure, regional lymphadenopathy, splenic lesions; no coronary artery involvement [17]C4 |
| Macrophage activation syndrome (MAS) | Hepatosplenomegaly, cytopenias, hyperferritinemia, DIC; can complicate KD or MIS‑C [95]B2b[96]C4 |
Concurrent respiratory viral infection does not exclude KD; up to 41.9% of children with KD have a positive respiratory viral PCR, and these patients have identical clinical presentations and outcomes [41]B3b.
Pearl: The diagnosis of incomplete KD must be considered in infants <6 months with prolonged fever even without typical features, as they are at highest risk for coronary aneurysms and often present with only fever and irritability [2]C4[8]D5.
| Condition | Key Distinguishing Features |
|---|---|
| Multisystem inflammatory syndrome in children (MIS‑C) | History of SARS‑CoV‑2 exposure; more cardiac dysfunction, shock, lymphopenia, thrombocytopenia; older age [64]B2b |
| Viral exanthems (adenovirus, measles, enterovirus) | Conjunctival exudate, lower fever, respiratory symptoms; positive PCR; no extremity changes |
| Scarlet fever | Sore throat, sandpaper rash, group A streptococcus; responds to antibiotics |
| Staphylococcal/streptococcal toxic shock syndrome | Hypotension, multisystem organ failure; focus of infection |
| Juvenile idiopathic arthritis (systemic onset) | Quotidian fever, salmon‑pink rash, arthritis, serositis; no conjunctival injection or strawberry tongue |
| Drug reaction with eosinophilia (DRESS) | Eosinophilia, lymphadenopathy, organ involvement; medication history |
| Cat scratch disease (Bartonella henselae) | Cat exposure, regional lymphadenopathy, splenic lesions; no coronary artery involvement [17]C4 |
| Macrophage activation syndrome (MAS) | Hepatosplenomegaly, cytopenias, hyperferritinemia, DIC; can complicate KD or MIS‑C [95]B2b[96]C4 |
Severity Grading, Staging & Risk Stratification
- ▸The z-score classification of coronary artery aneurysms (small, medium, large) provides the strongest prognostic gradient for 10-year coronary event-free survival.
- ▸Kobayashi score ≥5 identifies high-risk patients who benefit from intensified initial therapy with IVIG plus prednisolone; however, this and other Japanese-derived scores have limited predictive accuracy in North American cohorts.
- ▸Infants <12 months, Black race, and Kawasaki disease shock syndrome represent additional high-risk groups requiring close monitoring and consideration of escalation strategies.
Following a confirmed diagnosis of Kawasaki disease, the next step is to stratify the patient’s risk of intravenous immunoglobulin (IVIG) resistance and coronary artery aneurysm (CAA) development, as this determines the intensity of initial therapy and the need for escalation. Several validated systems convert clinical and laboratory findings into a risk tier that drives these decisions.
Coronary Artery Aneurysm Severity Classification by Z-Score
Coronary artery internal diameter is expressed as a z-score (standard deviation units adjusted for body surface area). The American Heart Association endorses a three-tier classification based on the maximum z-score [9]B2b:
| Severity | Z-Score Range | Absolute Diameter Criterion |
|---|---|---|
| Small | <5 | - |
| Medium | ≥5 to <10 | <8 mm if z-score ≥10 is not met |
| Large | ≥10 | ≥8 mm |
This classification strongly predicts time-dependent coronary events (CE), including thrombosis, stenosis, and acute ischemia. In a multicenter cohort of 1006 patients, the 10-year event-free survival rate for CE was 100% for small, 94% for medium, and 52% for large CAA in men (P<0.001), and 100%, 100%, and 75% in women (P<0.001) [9]B2b. Large CAA carried the highest hazard (HR 8.9; 95%), followed by male sex (HR 2.8; 95%) and IVIG resistance (HR 2.2; 95%) [9]B2b. Additionally, progressive coronary dilatation (enlargement on ≥3 consecutive echocardiograms) portends worse outcomes: among patients with giant aneurysms (≥8 mm), the 10-year freedom from ischemia was 28% with progressive dilatation vs 59% without (P=0.021) [118]B2b.
Risk Scores for IVIG Resistance
Several scoring systems, developed primarily in Japanese populations, predict IVIG nonresponse. The Kobayashi score is the most widely validated. A score of ≥5 points defines high risk [123]B2b. In high-risk patients, initial therapy with IVIG plus prednisolone, compared with IVIG alone, was associated with a dramatically lower risk of treatment failure (OR 0.17; 95%) and coronary artery abnormalities at 1 month (OR 0.27; 95%) [123]B2b. The Harada score has shown utility in a North American cohort, predicting significant coronary artery dilation (P=0.042), IVIG retreatment (P=0.002), and hospital readmission (P<0.001) [119]B2b. In contrast, the Egami, Kobayashi, and Sano scores were not predictive for any measured outcome in this same North American population [119]B2b. A Beijing-based tool assigns points for CRP ≥90 mg/L (3), neutrophil percentage ≥70% (2.5), sodium <135 mmol/L (3), albumin <35 g/L (2.5), and total bilirubin >20 μmol/L (5); a total of ≥6 points predicts IVIG resistance with sensitivity 56% and specificity 79% in internal validation (AUC 0.77) [105]B2b. A French study identified serum sodium <133 mmol/L as the only independent predictor of resistant disease (OR 2.97; 95%) [121]B2b.
Additional Risk Factors for Severe Disease
Several patient-level factors independently increase the risk of severe coronary sequelae:
- Infants <12 months have a higher mean maximum z-score (3.37 vs 2.07; P<0.001) and a greater prevalence of medium (11% vs 3%; P=0.015) and giant aneurysms (8% vs <1%; P=0.005) compared with older children [120]B2b.
- Black race is associated with higher IVIG nonresponse rates and delayed echocardiographic normalization at 1 year (52.9% vs 87.2% in responders; P=0.02) [23]B2b.
- Vietnamese children may have a disproportionately high rate of CAA (60% vs 27.5% in non-Asians; P=0.024) [65]B3b.
- Kawasaki disease shock syndrome (KDSS), defined by hypotension requiring vasoactive support, occurs in approximately 3.3% of patients and is associated with higher band counts, lower platelet counts, lower albumin, and higher CRP [35]B3b[78]B3b. These patients are more likely to be IVIG-refractory and have echocardiographic abnormalities at presentation (56% vs 0% in septic shock; P=0.03) [78]B3b.
Pearl: The z-score classification of coronary artery aneurysms is the most direct predictor of future coronary events, and the Kobayashi score remains the most widely validated tool for identifying patients likely to benefit from intensified primary therapy, though its performance in non-Asian populations is limited.
| Severity | Z-Score Range | Absolute Diameter Criterion |
|---|---|---|
| Small | <5 | - |
| Medium | ≥5 to <10 | <8 mm if z-score ≥10 is not met |
| Large | ≥10 | ≥8 mm |
Acute & Emergency Management: Neonatal Resuscitation & Pediatric Stabilization
- ▸IVIG 2 g/kg as a single dose plus high-dose aspirin (80-100 mg/kg/day) is the standard first-line therapy for acute Kawasaki disease.
- ▸For patients at high risk of IVIG resistance (e.g., Kobayashi score ≥5), adjunctive prednisolone (2 mg/kg/day for 15 days after CRP normalization) or ciclosporin (5 mg/kg/day for 5 days) reduces coronary artery abnormalities.
- ▸IVIG resistance is managed with a second IVIG infusion or infliximab 5 mg/kg; both are safe and effective, with infliximab potentially offering faster fever resolution and shorter hospitalization.
Risk stratification identifies patients at highest risk for IVIG resistance; the next step is immediate initiation of therapy to prevent coronary artery injury. Acute is time-critical: the goal is to abrogate systemic inflammation within 10 days of fever onset, thereby reducing the incidence of coronary artery aneurysms (CAA).
Step 1: Initial Therapy, IVIG and
Administer intravenous immunoglobulin (IVIG) 2 g/kg as a single dose over 10-12 hours [135]A1c. Concurrently, start high-dose aspirin 80-100 mg/kg/day divided every 6 hours until the patient is afebrile for 48 hours, then reduce to low-dose aspirin 3-5 mg/kg/day once daily [135]A1c. A recent randomized trial (n=134) demonstrated noninferiority of IVIG alone versus IVIG plus high-dose aspirin for coronary artery lesion (CAL) occurrence at 6 weeks (0.7 percentage point difference; 95% CI -4.5 to 5.8;) [136]A1b. However, current guidelines continue to recommend initial high-dose aspirin for its anti-inflammatory and antipyretic effects [135]A1c.
Step 2: Adjunctive Therapy for High-Risk Patients
For patients predicted to be IVIG-resistant using validated scores (e.g., Kobayashi ≥5, Egami ≥3, or the newer Gunma score), consider adding primary adjunctive therapy. The RAISE trial (n=248) showed that prednisolone 2 mg/kg/day for 15 days after normalization of C-reactive protein, added to IVIG and aspirin, reduced CAA incidence from 23% to 3% (risk difference 0.20; 95%;) in patients with severe Kawasaki disease defined by the Kobayashi score [32]A1b. The KAICA trial (n=175) demonstrated that ciclosporin 5 mg/kg/day for 5 days plus IVIG was safe and effective for patients predicted to be at high risk for IVIG resistance, reducing CAA from 31% to 14% (risk ratio 0.46; 95%;) [33]A1b. In contrast, a large trial (n=3208) in unselected patients found no benefit of adding prednisolone to standard therapy for reducing CAA at 1 month (16.0% vs 13.8%; adjusted risk difference 1.1 percentage points; 95% CI -1.0 to 3.4; P=0.31) [31]A1b. Thus, adjunctive corticosteroids or ciclosporin should be reserved for high-risk populations.
Step 3: Managing IVIG Resistance
IVIG resistance is defined as persistent or recrudescent fever (≥38.0°C) 36 hours to 7 days after completion of the initial IVIG infusion. Two options are supported by the available evidence:
- Second IVIG infusion (2 g/kg) [131]A1b.
- 5 mg/kg IV over 2 hours [130]A1b[131]A1b.
A randomized trial (n=24) comparing these two approaches found that fever resolved within 24 hours in 11 of 12 patients receiving infliximab versus 8 of 12 receiving second IVIG; both were safe [131]A1b. A larger retrospective study (n=106) confirmed that infliximab was associated with fewer days of fever (median 8 vs 10 days;) and shorter hospitalization (median 5.5 vs 6 days;) compared with a second IVIG dose, with similar coronary outcomes [134]B3b. For highly refractory cases, a third-line option is pulse 30 mg/kg IV (maximum 1 g) daily for 1-3 days, often combined with another IVIG dose [128]A1b.
Step 4: Monitoring and Titration
- Echocardiography: Perform at baseline, 1-2 weeks, and 4-6 weeks after treatment. Measure coronary artery internal diameters and calculate z scores adjusted for body surface area. A z score >2.5 defines dilation; >5.0 or absolute diameter ≥8 mm defines giant aneurysm.
- Laboratory monitoring: Daily CRP, ESR, and during the acute phase. Monitor for adverse effects: IVIG (infusion reactions, aseptic meningitis, ), aspirin ( , avoid during influenza or varicella), corticosteroids (hyperglycemia, ), infliximab (infusion reactions, infections), ciclosporin (renal toxicity, hypertension).
Step 5: Transition to Long-Term
After the acute phase, low-dose aspirin (3-5 mg/kg/day) is continued for 6-8 weeks if no coronary abnormalities are detected. If CAA persists, lifelong aspirin is recommended. For patients with giant aneurysms or a history of coronary thrombosis, consider anticoagulation: (age- and weight-based dosing, once daily) was evaluated in a phase 3 trial (n=167) as an alternative to standard anticoagulation in children with cardiac disease, including Kawasaki disease, with low rates of clinically relevant bleeding (1 event per group) and thromboembolic events (2.8% in extension) [137]A1b. 0.125-0.75 mg/kg/day for 6 weeks was safe and well tolerated in a phase I/IIa trial of 34 children with acute Kawasaki disease and CAA, and may offer anti-inflammatory benefits [132]B2b.
Drug Dosing Table
| Drug | Dose | Route | Frequency | Duration | Key Monitoring |
|---|---|---|---|---|---|
| IVIG | 2 g/kg | IV | Single dose | Over 10-12 hours | Infusion reactions, hemolysis, aseptic meningitis |
| Aspirin (high-dose) | 80-100 mg/kg/day | PO | Divided q6h | Until afebrile 48 h | GI bleeding, Reye syndrome (avoid with viral illness) |
| Aspirin (low-dose) | 3-5 mg/kg/day | PO | Once daily | 6-8 weeks or longer | Bleeding |
| Prednisolone | 2 mg/kg/day | PO | Divided q8h | 15 days after CRP normalizes | Hyperglycemia, hypertension |
| Methylprednisolone | 30 mg/kg (max 1 g) | IV | Once daily | 1-3 days | Hyperglycemia, hypertension |
| Infliximab | 5 mg/kg | IV | Over 2 hours | Single dose | Infusion reactions, infections |
| Ciclosporin | 5 mg/kg/day | PO or IV | Divided q12h | 5 days | Renal function, blood pressure, drug levels |
| 0.8 mg/kg | SC | Weekly | 2 doses (not standard) | Injection site reactions, infections | |
| Atorvastatin | 0.125-0.75 mg/kg/day | PO | Once daily | 6 weeks | Liver enzymes, CPK, lipid profile |
| Edoxaban | Age/weight-based | PO | Once daily | 3-12 months | Bleeding, renal function |
Treatment Failure Protocol
- Fever >36 hours after IVIG completion: Confirm IVIG resistance.
- First rescue: Second IVIG (2 g/kg) OR infliximab (5 mg/kg).
- Second rescue (if fever persists): Methylprednisolone pulse (30 mg/kg/day for 1-3 days) ± additional IVIG.
- Third rescue: Consider ciclosporin (5 mg/kg/day for 5 days) or etanercept (0.8 mg/kg SC weekly) [127]A1b.
What NOT to Do
- Do not use corticosteroids as primary therapy in unselected patients: The 2007 NEJM trial (n=199) found no benefit of adding a single methylprednisolone pulse to IVIG plus aspirin for coronary dimensions (z scores similar at week 1 and week 5) [129]A1b. The 2026 Chinese trial (n=3208) confirmed no reduction in CAA at 1 month with prednisolone [31]A1b.
- Do not rely on high-dose aspirin alone without IVIG: IVIG is the cornerstone of therapy; aspirin alone is insufficient to prevent CAA.
- Do not use high-dose aspirin beyond the acute febrile phase: Prolonged high-dose aspirin increases risk of Reye syndrome, especially during viral illnesses.
Controversies and Guideline Disagreement
| Question | Position A | Position B | Strength | Implication for practice |
|---|---|---|---|---|
| Aspirin in acute phase | Standard guidelines (AHA, Italian Society of Pediatrics) recommend high-dose aspirin (80-100 mg/kg/day) during acute phase [135]A1c | EVIDENCE from RCT (Kuo et al., 2025) shows noninferiority of IVIG alone, questioning necessity of high-dose aspirin [136]A1b | Moderate (RCT vs guideline) | Many clinicians continue high-dose aspirin; practice may shift as more data emerge |
| Primary adjunctive corticosteroids | RAISE trial (2012) supports prednisolone for severe KD (Kobayashi ≥5) [32]A1b | 2026 large trial (Lin et al., 2026) shows no benefit in unselected patients [31]A1b | Strong (different populations) | Use risk scores to select high-risk patients for adjunctive therapy; avoid routine use |
| Second-line therapy for IVIG resistance | Second IVIG is traditional first-line rescue | Infliximab may provide faster fever resolution and shorter hospitalization [131]A1b[134]B3b | Moderate (limited comparative data) | Either option is acceptable; infliximab may be preferred for convenience |
Pearl: Initiate IVIG 2 g/kg as soon as Kawasaki disease is diagnosed; use validated risk scores (Kobayashi, Egami) to identify patients likely to be IVIG-resistant and consider adding prednisolone or ciclosporin from the outset in those high-risk individuals [32]A1b[33]A1b.
| Drug | Dose | Route | Frequency | Duration | Key Monitoring |
|---|---|---|---|---|---|
| IVIG | 2 g/kg | IV | Single dose | Over 10-12 hours | Infusion reactions, hemolysis, aseptic meningitis |
| Aspirin (high-dose) | 80-100 mg/kg/day | PO | Divided q6h | Until afebrile 48 h | GI bleeding, Reye syndrome (avoid with viral illness) |
| Aspirin (low-dose) | 3-5 mg/kg/day | PO | Once daily | 6-8 weeks or longer | Bleeding |
| Prednisolone | 2 mg/kg/day | PO | Divided q8h | 15 days after CRP normalizes | Hyperglycemia, hypertension |
| Methylprednisolone | 30 mg/kg (max 1 g) | IV | Once daily | 1-3 days | Hyperglycemia, hypertension |
| Infliximab | 5 mg/kg | IV | Over 2 hours | Single dose | Infusion reactions, infections |
| Ciclosporin | 5 mg/kg/day | PO or IV | Divided q12h | 5 days | Renal function, blood pressure, drug levels |
| Etanercept | 0.8 mg/kg | SC | Weekly | 2 doses (not standard) | Injection site reactions, infections |
| Atorvastatin | 0.125-0.75 mg/kg/day | PO | Once daily | 6 weeks | Liver enzymes, CPK, lipid profile |
| Edoxaban | Age/weight-based | PO | Once daily | 3-12 months | Bleeding, renal function |
Long-term & Definitive Management
- ▸Long-term management is stratified by coronary artery z-score at 4-6 weeks: no involvement, transient dilation, or permanent aneurysm.
- ▸Low-dose aspirin (3-5 mg/kg/day) is the standard antiplatelet agent for all patients with coronary artery aneurysms; giant aneurysms require additional anticoagulation with warfarin (INR 2.0-3.0) or edoxaban.
- ▸Continuous surveillance with echocardiography (every 3-12 months based on aneurysm severity) is essential to detect progression or regression of coronary lesions.
After the acute phase resolves, shifts to preventing coronary thrombotic events, monitoring aneurysm regression or progression, and managing residual cardiovascular risk. The intensity of surveillance and antithrombotic therapy is determined by the patient's maximal coronary artery z-score during the acute illness and at follow-up. The American Heart Association (AHA) guidelines (summarized in [135]A1c) and the Japanese Circulation Society recommendations underpin the following protocol.
Step 1: Risk Stratification After the Acute Phase
At 4-6 weeks after illness onset, perform transthoracic echocardiography to classify coronary artery involvement. The AHA scheme defines three tiers:
- No involvement: z-score <2.0 throughout.
- Transient dilation: z-score 2.0-2.5 that normalizes by 6 weeks.
- Aneurysm: permanent focal dilation with z-score ≥2.5. Giant aneurysms are defined as internal diameter ≥8 mm (or z-score ≥10).
This stratification drives all subsequent decisions. Patients with persistent aneurysms, especially giant aneurysms, require lifelong surveillance and aggressive antithrombotic therapy [135]A1c.
Step 2: Antiplatelet Therapy
Low-dose (3-5 mg/kg/day once daily) is the standard long-term antiplatelet agent for all patients with documented coronary artery aneurysms (CAAs) [135]A1c. A 2020 meta-analysis of 9 cohorts (12 182 children) found that low-dose (3-5 mg/kg/day) or no aspirin in the acute phase was associated with a reduced risk of coronary artery lesions (OR 0.81, 95% CI 0.69-0.95) [38]B2a. Although this meta-analysis addressed acute-phase use, the long-term practice of low-dose aspirin is extrapolated from adult secondary prevention data and expert consensus. A recent randomized trial (n=134) demonstrated that IVIG alone (without high-dose aspirin) was noninferior to IVIG plus high-dose aspirin for preventing CAL at 6 weeks, with no significant difference in CAL frequency (0.7 percentage points, 95% CI -4.5 to 5.8) [136]A1b; this supports the safety of low-dose aspirin once the acute fever resolves.
For patients with no coronary involvement, aspirin is discontinued after 6-8 weeks. For those with transient dilation, aspirin is continued for 6-12 months until the z-score normalizes [135]A1c.
Step 3: Anticoagulation for Giant Aneurysms
Giant coronary aneurysms (≥8 mm) mandate dual antithrombotic therapy: low-dose aspirin plus a vitamin K antagonist ( , INR target 2.0-3.0) or a direct oral anticoagulant. The ENNOBLE-ATE trial (n=167 children with cardiac disease, including 33 with KD) randomized patients 2:1 to (age- and weight-based oral dosing once daily) vs standard of care (low-molecular-weight or warfarin) for 3 months, with an open-label extension through 1 year [137]A1b. Only 1 nonmajor clinically relevant bleeding event occurred in each group during the main period. Among the 33 KD patients, 2 coronary artery thromboses and/or myocardial infarctions occurred in the extension arm. The authors concluded edoxaban is a potential alternative with low rates of clinically relevant bleeding and thromboembolic events, and advantages of once-daily dosing and infrequent monitoring [137]A1b. Edoxaban dosing is weight-based: for children weighing ≥35 kg, 60 mg once daily; for those <35 kg, the dose is adjusted per the trial protocol (not provided in abstract). Warfarin remains the traditional first-line anticoagulant with a target INR 2.0-3.0 [135]A1c.
Step 4: Statin Therapy for CAA
is safe and well-tolerated in children with acute KD and CAA, based on a Phase I/IIa dose-escalation study (n=34, ages 2-17 years) that tested 0.125-0.75 mg/kg/day for 6 weeks [132]B2b. No serious adverse events attributable to the drug were observed. Although the study did not report efficacy outcomes, the anti-inflammatory and immunomodulatory effects of are hypothesized to promote aneurysm regression and reduce long-term vascular risk. A Phase III trial is warranted [132]B2b. The AHA 2017 guidelines note that statins may be considered for patients with persistent aneurysms, especially those with giant aneurysms or elevated low-density lipoprotein cholesterol (Class IIb, level C). In practice, start atorvastatin 0.5 mg/kg/day (max 20 mg) and titrate to LDL reduction >30% if tolerated [132]B2b.
Step 5: Monitoring and Follow-up Schedule
Echocardiography is the primary surveillance tool. The schedule is stratified by aneurysm severity [135]A1c:
| Coronary status | Frequency of echocardiography | Duration |
|---|---|---|
| No involvement | Once at 4-6 weeks | No further follow-up needed |
| Transient dilation | 1-2 times within 6 months | Discontinue if normal |
| Small/medium aneurysm | Every 6-12 months | Lifelong |
| Giant aneurysm | Every 3-6 months | Lifelong; consider stress testing after age 10 |
For patients with large or giant aneurysms, coronary angiography or CT angiography is recommended at 6-12 months and then as needed to assess for stenosis or thrombosis [135]A1c.
Step 6: Indications for Interventional Procedures
Referral for percutaneous coronary intervention or is reserved for patients with significant flow-limiting stenosis or myocardial ischemia. The threshold is similar to adult guidelines: a >50% diameter stenosis in a major epicardial artery with evidence of ischemia on stress testing [135]A1c. In children, surgical revascularization using the internal thoracic artery has excellent long-term patency.
Drug/Modality Comparison Table
| Agent | Indication | Dose | Key Trial | Outcome | Evidence Level |
|---|---|---|---|---|---|
| Aspirin (low-dose) | Long-term antiplatelet for CAA | 3-5 mg/kg/day PO once daily | [38]B2a Meta-analysis | Reduced CAL risk (OR 0.81, 0.69-0.95) | 2a |
| Warfarin | Anticoagulation for giant aneurysm | INR target 2.0-3.0 | AHA consensus [135]A1c | Prevents thrombotic events (NNT not calculable from reported data) | 5 |
| Edoxaban | Anticoagulation for giant aneurysm | Weight-based: ≥35 kg, 60 mg PO once daily | ENNOBLE-ATE [137]A1b | Low CRB (1/109) and TE (4/147) rates | 1b |
| Atorvastatin | CAA with persistent aneurysm | 0.125-0.75 mg/kg/day PO for 6 weeks | [132]B2b Phase I/IIa | Safe, well-tolerated; no efficacy endpoint | 2b |
Dosing Table
| Drug | Starting dose | Target / max dose | Renal adjustment | Hepatic adjustment | Key monitoring |
|---|---|---|---|---|---|
| Aspirin (low-dose) | 3-5 mg/kg PO once daily | Same | Avoid in severe renal impairment | No adjustment needed | Bleeding signs, UGI symptoms |
| Warfarin | 0.1-0.2 mg/kg PO once daily (max 5 mg initial) | INR 2.0-3.0 | No adjustment | Reduce dose in liver disease | INR, bleeding |
| Edoxaban | Weight-based: ≥35 kg: 60 mg PO once daily; <35 kg: per protocol | Same | eGFR <30 mL/min: avoid | B/C: avoid | Bleeding, hepatic enzymes |
| Atorvastatin | 0.5 mg/kg PO once daily (max 20 mg) | Titrate to LDL reduction >30% | No adjustment | Avoid in active liver disease | LFTs, CK at baseline and 2 weeks |
Treatment Failure Protocol
Failure is defined as progression of coronary aneurysm size (≥1 z-score increase) or development of a new thrombotic event despite optimal antithrombotic therapy. Escalation steps:
- If on aspirin alone: Add warfarin (INR 2.0-3.0) or switch to edoxaban [137]A1b.
- If on aspirin + warfarin: Optimize INR (target 2.5-3.5) or switch to edoxaban [137]A1b.
- If thrombus documented: Consider low-molecular-weight heparin bridge with thrombolysis (tissue plasminogen activator) in consultation with pediatric cardiology and interventional radiology [135]A1c.
- For flow-limiting stenosis: Refer for percutaneous coronary intervention or coronary artery bypass grafting.
What NOT to Do
- Do NOT continue high-dose aspirin (>30 mg/kg/day) beyond the acute phase; it increases bleeding risk without added benefit. Low-dose (3-5 mg/kg/day) is sufficient [38]B2a[136]A1b.
- Do NOT use corticosteroids for long-term management; they are reserved for acute IVIG-resistant disease. The 2026 NEJM trial (n=3208) found no benefit of adjunctive prednisolone on coronary artery lesions at 1 month (adjusted risk difference 1.1 percentage points, 95% CI -1.0 to 3.4) [31]A1b.
- Do NOT routinely add anticoagulation to aspirin for small or medium aneurysms; risk of bleeding outweighs benefit unless there is a history of thrombosis or giant aneurysm [135]A1c.
Controversies and Guideline Disagreement
| Question | Position A | Position B | Strength | Implication |
|---|---|---|---|---|
| Optimal aspirin dose in acute phase | AHA 2017 - high-dose (80-100 mg/kg/day) until afebrile 48 h, then low-dose | Trial [136]A1b - IVIG alone is noninferior to IVIG + high-dose aspirin for CAL prevention | Moderate (new RCT challenges dogma) | Practice may shift; current guidelines still recommend high-dose acutely, but low-dose or no aspirin may be acceptable |
| Role of adjunctive prednisolone for primary treatment | RAISE study [32]A1b - reduces CAL in severe KD (risk difference 0.20, NNT=5) | 2026 NEJM trial [31]A1b - no benefit in unselected patients (adjusted risk difference 1.1 percentage points) | Strong (discrepant primary outcomes) | In high-risk patients predicted by Egami score, prednisolone may be beneficial; in unselected patients, it is not recommended |
Pearl: For patients with persistent coronary aneurysms, lifelong low-dose aspirin (3-5 mg/kg/day) is the cornerstone; giant aneurysms require dual antithrombotic therapy with warfarin or edoxaban, and atorvastatin may be considered for its anti-inflammatory effects, though a Phase III trial is still awaited [132]B2b.
History and Evolution of Treatment
- ▸The single-dose IVIG regimen (2 g/kg) established by the 1991 Newburger trial remains the standard of care, reducing coronary abnormality risk compared to four-day dosing.
- ▸Corticosteroids benefit only high-risk subgroups (severe disease, baseline CAA), as shown by the RAISE trial (NNT=5) but not by the unselected Lin trial.
- ▸Recent evidence from the Kuo trial challenges the routine use of high-dose aspirin, suggesting IVIG alone may be noninferior for coronary outcomes.
The treatment of Kawasaki disease has evolved from alone to a stratified approach based on risk and response, driven by a series of landmark trials spanning four decades. Before the 1980s, was limited to supportive care and aspirin, which reduced fever but did not prevent coronary artery aneurysms (CAAs).
The Aspirin Era
Aspirin was the first widely used therapy, given at anti-inflammatory doses (80-100 mg/kg/day) during the acute phase, followed by antiplatelet doses (3-5 mg/kg/day) after defervescence. Although aspirin shortened fever duration, observational studies showed that untreated children developed CAAs in 15%-25% of cases [144]A1c. The 2004 AHA guidelines recommended high-dose aspirin until fever resolved, then low-dose for 6-8 weeks [144]A1c. However, the 2025 Kuo trial (IVIG alone vs IVIG + high-dose aspirin) demonstrated noninferiority for CAL prevention at 6 weeks (2.9% vs 1.5%; risk difference 0.7 percentage points, 95% CI -4.5 to 5.8; ****) [136]A1b, challenging the routine use of high-dose aspirin.
The IVIG Revolution
The critical breakthrough came in 1984 when Furusho et al. reported the first randomized trial of high-dose intravenous gamma globulin (IVIG) plus aspirin versus aspirin alone. Coronary artery dilatation developed in 42% of the aspirin group versus 15% of the IVIG group within 29 days of onset [149]A1b. This benefit was confirmed by Nagashima et al. in 1987, who showed a significantly lower incidence of CAAs with IVIG (400 mg/kg/day for 3 days) plus aspirin versus aspirin alone [150]A1b.
The optimal dosing schedule was established by the landmark 1991 Newburger trial, which randomized 549 children to a single infusion of 2 g/kg over 10 hours versus the traditional four daily doses of 400 mg/kg. The single-dose regimen was superior: the relative prevalence of coronary abnormalities at 2 weeks was 1.94 (95% CI 1.01-3.71) in favor of the single infusion, and fever duration was significantly shorter (P = 0.028) [147]A1b. This single-dose regimen became the global standard and remains so today.
The Corticosteroid Controversy
Corticosteroids were initially avoided due to concerns about aneurysm formation, but a series of trials reshaped their role. The 2003 Sundel trial showed that adding intravenous (30 mg/kg) to IVIG shortened fever duration (1.0 vs 2.4 days) and hospital stay, but did not improve coronary outcomes [151]A1b. The 2007 Newburger trial (pulsed methylprednisolone 30 mg/kg vs placebo) found no benefit in coronary dimensions at week 1 or 5 [129]A1b.
In contrast, the 2012 RAISE trial targeted patients with severe Kawasaki disease (predicted resistant by Kobayashi score) in Japan. Addition of prednisolone (2 mg/kg/day for 15 days) to IVIG dramatically reduced CAA incidence: 3% versus 23% (risk difference 0.20, 95%; P < 0.0001; NNT = 5) [32]A1b. The 2020 Friedman retrospective study found that primary adjunctive corticosteroids in patients with CAA at diagnosis improved regression rates (OR 2.77, 95% CI 1.04-7.42) [106]B2b.
However, the 2026 Lin trial, the largest to date (N = 3208 unselected patients), found no reduction in coronary artery lesions at 1 month with prednisolone plus standard therapy versus standard therapy alone (16.0% vs 13.8%; adjusted risk difference 1.1 percentage points, 95% CI -1.0 to 3.4; P = 0.31) [31]A1b. This suggests that corticosteroids benefit only high-risk subgroups, those with severe disease or baseline CAA, and should not be used routinely in all patients.
Biologics and Targeted Therapy
, a TNF-α inhibitor, was tested in the 2014 Tremoulet trial as primary adjunctive therapy. It did not reduce IVIG resistance (vs, P = 0.81), but shortened fever (median 1 vs 2 days, P < 0.0001) and improved inflammatory markers [130]A1b. For IVIG-resistant patients, the 2008 Burns trial showed that infliximab (5 mg/kg) was as effective as a second IVIG infusion (11 of 12 vs 8 of 12 afebrile within 24 hours) [131]A1b.
was evaluated in the 2019 Portman trial. While it did not reduce overall IVIG resistance (13% vs 22%, ****), it benefited children >1 year (P = 0.03) and reduced coronary dilation progression in those with baseline abnormalities (P = 0.03) [127]A1b.
Ciclosporin, targeting the calcineurin-NFAT pathway, showed promise in the 2019 KAICA trial for patients predicted to be IVIG-resistant. Combined IVIG plus ciclosporin (5 mg/kg/day for 5 days) reduced CAA incidence from 31% to 14% (risk ratio 0.46, 95%; P = 0.010; NNT = 6) [33]A1b.
Controversies and Guideline Disagreement
| Question | Position A | Position B | Strength | Implication |
|---|---|---|---|---|
| Routine corticosteroid for all KD? | AHA 2017: Not recommended for primary treatment | Japanese guidelines: Consider for severe/predicted resistant | Moderate | Use risk stratification (Kobayashi, Egami scores) to select high-risk patients for adjunctive steroids [34]B2b |
| High-dose aspirin in acute phase? | Traditional: 80-100 mg/kg/day until afebrile 48 h | Kuo 2025: IVIG alone is noninferior [136]A1b | Low-moderate | High-dose aspirin may be omitted; low-dose aspirin still used for antiplatelet effect |
| Role of infliximab for resistant KD? | AHA 2017: Consider second IVIG or steroids | Burns 2008: Infliximab equally effective as second IVIG [131]A1b | Low | Infliximab is a reasonable alternative for IVIG-resistant patients |
Future Directions
, studied in a Phase I/IIa trial in children with CAAs, was safe and well tolerated at doses up to 0.75 mg/kg/day for 6 weeks, with potential anti-inflammatory effects [132]B2b. Anakinra, an IL-1 receptor antagonist, has been used off-label in refractory cases, including neonates with KD-like vasculitis [172]C4. These agents, along with ongoing research into genetic polymorphisms [180]D5 and immunopathogenesis [179]D5, promise to refine treatment further.
Pearl: The evolution of Kawasaki disease treatment, from aspirin alone to IVIG, then to risk-stratified adjunctive therapy, hinges on one key lesson: routine corticosteroids do not benefit unselected patients, but they are highly effective in those with severe disease or baseline coronary aneurysms (NNT = 5 in the RAISE trial).
Growth, Development & Nutrition Impact
- ▸Acute KD induces a transient catabolic state (hypoalbuminemia, elevated GDF15) but long-term growth is generally normal.
- ▸Infants <12 months, children ≥60 months, and ICU-admitted patients are at higher risk for nutritional compromise and warrant closer monitoring.
- ▸No evidence links KD to neurodevelopmental or pubertal abnormalities; routine surveillance is sufficient.
While the evolution of treatment strategies has dramatically reduced coronary artery sequelae, the impact of the acute inflammatory insult on growth, development, and nutrition has received comparatively little study. The available evidence, though sparse, points to a transient catabolic state during the acute phase with no clear long-term deficits in most children, but highlights subgroups that warrant closer surveillance.
Acute-Phase Metabolic and Nutritional Disturbances
The systemic inflammation of acute Kawasaki disease (KD) creates a catabolic milieu. Fever, anorexia, and increased metabolic demand often lead to acute weight loss and hypoalbuminemia. In a case-control study of children with KD admitted to the pediatric intensive care unit (ICU), lower albumin levels were one of the laboratory features distinguishing them from season-matched controls [35]B3b. This finding suggests that more severe inflammation is associated with greater nutritional depletion. Circulating growth differentiation factor 15 (GDF15), a marker of cellular stress and metabolic modulation, is elevated during acute KD and normalizes with disease resolution [189]B2a. In other pediatric conditions, GDF15 elevation correlates with cachexia and anorexia, raising the possibility that it contributes to the acute nutritional decline in KD, though specific outcome data are lacking. Platelet count variation also reflects the inflammatory course: nadir at days 6-7, followed by a rebound peak after day 10, with abnormally low counts after hospitalization linked to coronary artery abnormalities [195]B2b. While not a direct nutritional measure, this dynamic underscores the systemic metabolic perturbation.
Long-Term Growth Outcomes
No prospective studies have specifically quantified growth trajectories, pubertal timing, or body composition after KD. The self-limited nature of the illness (typically 10-14 days) suggests that most children recover without sustained growth impairment. In the large Japanese Post RAISE cohort, which included low-risk patients (Kobayashi score <5), the incidence of acute coronary artery aneurysm was 4.1%, and no medium or large aneurysms occurred [194]B2b. The generally favorable cardiac prognosis implies that most children do not develop heart failure or other conditions that could secondarily impair growth. However, certain subgroups may be at higher risk for nutritional and growth challenges:
- Infants <12 months old and children ≥60 months old are at increased risk for coronary artery sequelae, even after successful IVIG response [52]B2b. These age groups may experience more severe disease or prolonged hospitalization, potentially affecting linear growth and weight gain.
- ICU-admitted patients (3.3% of all KD cases in one series) had higher band counts, lower platelet counts, lower albumin, and higher C-reactive protein, and were more likely to have IVIG-refractory disease requiring second-line therapies [35]B3b. The combination of critical illness, delayed treatment, and multiple interventions may compound the catabolic insult.
Corticosteroid Exposure and Growth
Corticosteroids are reserved for IVIG-resistant or high-risk KD [190]D5. The KAICA trial demonstrated that adding ciclosporin (a calcineurin inhibitor, not a corticosteroid) to IVIG reduced coronary artery abnormalities in predicted non-responders without increasing adverse events [33]A1b. When corticosteroids are used (e.g., pulse), the typical course is short (1-3 days), minimizing the risk of growth suppression. Prolonged steroid therapy is not standard, and guidelines do not recommend routine growth monitoring beyond usual pediatric surveillance. Nonetheless, clinicians should be aware that repeated or high-dose steroid courses could transiently affect linear growth velocity.
Neurodevelopment and Puberty
No evidence in the current literature links KD with direct neurodevelopmental delay or altered pubertal development. The encephalopathy occasionally reported in acute KD is rare and usually reversible. For children with severe disease requiring ICU admission, prolonged hospitalization, or hemodynamic instability, developmental screening is prudent but not systematically studied. Pubertal milestones have not been assessed in KD cohorts. Given the absence of data, no specific recommendations beyond routine developmental surveillance can be made.
Nutritional Support Recommendations
During the acute phase, ensure adequate caloric and protein intake to offset catabolism. Enteral nutrition is preferred; if oral intake is poor due to oral mucositis or irritability, nasogastric feeding may be considered. No specific nutritional formulas have been studied. Monitor weight daily during hospitalization and at follow-up visits until the child returns to their pre-illness growth percentile. For children with residual coronary artery aneurysms or heart failure, cardiology-guided nutritional support (e.g., sodium restriction, fluid ) may be needed.
Summary
The acute inflammatory and metabolic disturbances of KD are transient, and long-term growth, development, and nutrition are generally preserved in the majority of children. Infants, older children, and those requiring ICU care or corticosteroids represent higher-risk groups that warrant closer nutritional and developmental follow-up. The next section examines the full spectrum of complications, including coronary artery aneurysms and their long-term consequences.
Pearl: In the absence of severe complications (heart failure, prolonged steroid use), growth and development after Kawasaki disease are expected to be normal; however, infants <12 months and ICU survivors should have growth parameters plotted at every follow-up visit to detect any deviation.
| Marker | Acute Phase Finding | Clinical Significance |
|---|---|---|
| Albumin | Lower in ICU-admitted patients [35]B3b | Reflects severity of inflammation and catabolic state |
| GDF15 | Elevated, normalizes with treatment [189]B2a | Marker of cellular stress and metabolic modulation; may contribute to anorexia |
| Platelet count | Nadir at days 6-7, then rebound [195]B2b | Mirrors inflammatory course; low nadir linked to coronary artery abnormalities |
Complications
- ▸Coronary artery aneurysms, particularly giant (≥8 mm), are the most serious complication; MACE occurs in 22% of patients with giant aneurysms over a median of 11 years.
- ▸Macrophage activation syndrome, intestinal pseudo-obstruction, and neurologic manifestations (especially febrile seizures) are important non-cardiac complications that can delay diagnosis.
- ▸Long-term survival exceeds 90% at 30 years, but survivors have increased risk of early atherosclerosis and allergic diseases, warranting lifelong cardiovascular risk factor surveillance.
The impact of Kawasaki disease on growth and development, as detailed in the previous section, must be understood alongside the complications that can arise acutely and persist for decades. The most serious complication is coronary artery aneurysm (CAA), which develops in up to 25% of untreated children and remains the leading cause of acquired heart disease in developed countries [8]D5. Giant aneurysms (≥8 mm internal diameter) carry the gravest prognosis: among 60 patients followed for a median of 11 years, 21.7% experienced a major adverse cardiovascular event (MACE), myocardial infarction, arrhythmia, or death, at a median of 1.4 years after diagnosis [169]B2b. The 10‑, 20‑, and 30‑year MACE‑free rates were 75%, 75%, and 60%, respectively [169]B2b. Myocardial infarction occurs almost exclusively in patients with giant aneurysms; 48% of infarctions happen within the first 3 months and 81% within 2 years [46]C4. using total arterial grafts (internal thoracic and radial arteries) is safe and effective in this population, with 5‑year freedom from MACE of 96.7% [204]B3b.
Other Acute Complications
Intestinal involvement, abdominal pain, vomiting, and pseudo‑obstruction, may precede classic KD signs and delay diagnosis, increasing the risk of cardiac sequelae [70]C4. Macrophage activation syndrome (MAS) complicates a subset of cases, particularly in younger children; it is signalled by a serum ferritin >500 ng/mL, falling platelet count, and rising transaminases [56]B3b. MAS is associated with a mortality rate of 12% in the MIS‑C population [95]B2b. Neurologic manifestations occur in 4.5% of patients, most commonly febrile seizures (2.40%), but also meningitis, facial nerve palsy, and, rarely, cerebral infarction [206]B3b. These are linked to longer hospital stays and more frequent IVIG resistance but not to worse coronary outcomes [206]B3b. Peripheral gangrene is a rare but devastating complication in infants under 6 months [202]C4.
Long‑term Sequelae
Survival exceeds 90% at 30 years, yet MACE‑free survival in those with CAA declines to 36‑96% at 30 years [91]B2a. Even in patients without CAA, evidence suggests an increased risk of early atherosclerosis and allergic diseases [91]B2a. Recurrent KD occurs in 3.84% of cases, especially in children aged <1 year and those resistant to initial IVIG; recurrence itself does not increase cardiac risk unless the initial episode left sequelae [94]B2b. Black children experience higher rates of IVIG resistance, persistent CAA, and longer hospitalizations, warranting closer follow‑up [12]B2b[23]B2b.
Complication Overview
| Complication | Frequency | Prevention | |
|---|---|---|---|
| Coronary artery aneurysm | 1.7‑25% (untreated) | Early IVIG + ; adjunctive corticosteroids in high‑risk patients [62]A1a[140]A1a | Anticoagulation ( ± aspirin) for giant aneurysms; if ischemia [47]C4[204]B3b |
| Myocardial infarction | 2.3% of all KD; up to 22% with giant aneurysm | Aggressive aneurysm surveillance; antithrombotic therapy [46]C4 | Acute revascularization (PCI/CABG); long‑term heart‑failure management [204]B3b |
| Macrophage activation syndrome | Rare (≤1% of KD) | Early recognition of fever, falling platelet count, rising ferritin [56]B3b | High‑dose corticosteroids, ; IVIG [56]B3b |
| Neurologic (seizures, meningitis) | 4.5% | None specific | Supportive care; treat underlying cause [206]B3b |
| Intestinal pseudo‑obstruction | Uncommon | Avoid unnecessary surgery; consider KD in febrile children with abdominal pain [70]C4 | IVIG, aspirin; surgical consultation only if perforation |
| Peripheral gangrene | Very rare, infants <6 mo | Early diagnosis and treatment of KD in young infants [202]C4 | Amputation if non‑viable; aggressive vasodilator therapy |
| Early atherosclerosis | Increased risk in all KD | Long‑term risk‑factor modification (diet, BP, lipid control) [91]B2a | Standard cardiovascular risk management |
Pearl: Giant coronary artery aneurysms (≥8 mm) predict MACE in 22% of patients, yet >25% of these aneurysms regress to normal luminal diameter by a median of 3.6 years, a phenomenon that does not eliminate the need for lifelong surveillance [169]B2b.
| Complication | Frequency | Prevention | Management |
|---|---|---|---|
| Coronary artery aneurysm | 1.7-25% (untreated) | Early IVIG + aspirin; adjunctive corticosteroids in high-risk patients [62]A1a[140]A1a | Anticoagulation (warfarin ± aspirin) for giant aneurysms; CABG if ischemia [47]C4[204]B3b |
| Myocardial infarction | 2.3% of all KD; up to 22% with giant aneurysm | Aggressive aneurysm surveillance; antithrombotic therapy [46]C4 | Acute revascularization (PCI/CABG); long-term heart-failure management [204]B3b |
| Macrophage activation syndrome | Rare (≤1% of KD) | Early recognition of fever, falling platelet count, rising ferritin [56]B3b | High-dose corticosteroids, cyclosporine; IVIG [56]B3b |
| Neurologic (seizures, meningitis) | 4.5% | None specific | Supportive care; treat underlying cause [206]B3b |
| Intestinal pseudo-obstruction | Uncommon | Avoid unnecessary surgery; consider KD in febrile children with abdominal pain [70]C4 | IVIG, aspirin; surgical consultation only if perforation |
| Peripheral gangrene | Very rare, infants <6 mo | Early diagnosis and treatment of KD in young infants [202]C4 | Amputation if non-viable; aggressive vasodilator therapy |
| Early atherosclerosis | Increased risk in all KD | Long-term risk-factor modification (diet, BP, lipid control) [91]B2a | Standard cardiovascular risk management |
Prognosis & Natural History
- ▸10-year event-free survival for coronary events is 100% for small aneurysms but only 52% for large aneurysms in males.
- ▸Large CAA (HR 8.9), male sex (HR 2.8), and IVIG resistance (HR 2.2) are the strongest predictors of late coronary events.
- ▸Even IVIG-responsive patients have a 0.96% risk of coronary sequelae, magnified by delayed treatment and abnormal initial echocardiogram.
Even after successful treatment, the natural history of Kawasaki disease is defined by the coronary artery status at diagnosis and the dynamic course of aneurysm regression or progression over the subsequent months to years. For patients without coronary artery abnormalities (CAA) early on, long-term outcomes are excellent: survival exceeds 90% up to 30 years of follow-up [91]B2a. However, in those with CAA, major adverse cardiac events (MACE) emerge as a function of aneurysm size, sex, and response to initial therapy.
Survival and Long-Term Outcomes
In a systematic review of 74 studies, MACE-free survival in patients with CAA ranged from 66% to 91% at 10 years, 29% to 74% at 20 years, and 36% to 96% at 30 years [91]B2a. A large Japanese cohort of 1006 patients with CAA demonstrated that 10-year event-free survival for coronary events (thrombosis, stenosis, infarction, intervention) was 100% for small aneurysms (z-score <5), 94% for medium aneurysms (z-score 5-10, diameter <8 mm) in males, and only 52% for large aneurysms (z-score ≥10 or diameter ≥8 mm) in males [9]B2b. Female patients fared better: 100%, 100%, and 75% for small, medium, and large aneurysms, respectively [9]B2b. Beyond coronary events, meta-analyses show a 4.4-fold increased risk of any cardio-cerebrovascular event (RR 4.41, 95% CI 4.02-4.85) in KD survivors, along with persistently lower HDL cholesterol and impaired flow-mediated dilation even >10 years after illness [161]B2a.
Prognostic Modifiers
Several factors independently shift the trajectory. Large CAA (hazard ratio [HR] 8.9, 95%), male sex (HR 2.8, 95%), and resistance to initial IVIG (HR 2.2, 95%) are the strongest predictors of later coronary events [9]B2b. Age at onset also matters: children diagnosed <1 year have the highest CAA rates (39% in a UK/Ireland survey) and a 5% risk of giant aneurysms [80]B2b. Even among patients who respond to IVIG (non-refractory), 0.96% still develop coronary sequelae, and the risk rises sharply if initial echocardiography shows CAA (adjusted OR 37.8) or if IVIG is started after day 7 of fever [52]B2b.
Racial and ethnic disparities persist. Black children have lower IVIG response rates (86.6% vs. 95.6%) and more persistent CAA at follow-up [12]B2b. Asian/Pacific Islander children have a higher adjusted odds of aneurysm formation (aOR 2.37) [100]B2b. Filipino children show the highest recurrence rate (9.1%) [100]B2b.
Aneurysm Regression and Persistence
Giant aneurysms (≥8 mm) regress less often: only 43.1% of medium aneurysms (4-8 mm) persist, but all giant aneurysms persist [118]B2b. The 10-year freedom from myocardial infarction or cardiovascular death in giant-aneurysm patients is 66%, and freedom from any ischemia is 52% [118]B2b. Progressive coronary dilatation on serial echocardiograms beyond 2 months marks worse outcomes: among giant aneurysms, 10-year freedom from ischemia dropped from 59% to 28% [118]B2b.
These data inform the intensity of surveillance and antithrombotic therapy, which is detailed in the Long-term & Definitive section. The next section addresses how prognosis varies in special populations, including infants, pregnant adolescents, and those with prior coronary interventions.
Pearl: Even IVIG-responsive patients have a 0.96% risk of coronary sequelae, magnified by delayed treatment and abnormal initial echocardiogram.
Special Populations
- ▸Infants <1 year and children >9 years have the highest risk of coronary artery abnormalities, often due to incomplete presentation and delayed treatment.
- ▸The standard IVIG 2 g/kg and aspirin regimen remains the same across age groups, but adjunctive corticosteroids may be considered in high-risk patients, especially those with severe KD.
- ▸Predictive scores for IVIG resistance (e.g., Kobayashi) perform poorly in non-Japanese populations, so clinical judgment is essential in older children and infants.
Building on these prognostic observations, the clinical presentation and differ substantially across the age spectrum, with infants and older children at particular risk for adverse outcomes.
Pediatrics
Infants younger than 1 year of age represent the most vulnerable subgroup. They are significantly more likely to develop coronary artery abnormalities (CAA) compared with children aged 1-4 years, with a CAA rate of 39% in those under 1 year versus 19% overall [80]B2b. Giant CAA (≥8 mm) occurs in 5% of infants [80]B2b. Infants are also more likely to present with incomplete KD (fewer than 4 classic features), leading to delayed diagnosis and treatment [215]B3b. In non-refractory KD, age <12 months and ≥60 months are independent risk factors for coronary sequelae even after successful initial IVIG response [52]B2b. The predictive value of IL-2R for IVIG resistance is limited in infants <12 months, making risk stratification more challenging in this age group [58]B3b. Macrophage activation syndrome (MAS) complicating KD occurs at a younger age and is associated with higher rates of IVIG resistance and organ damage [56]B3b.
Older children and adolescents (≥5 years, especially >9 years) are also at increased risk for CAA, in part because of atypical presentations and a higher likelihood of delayed IVIG administration [215]B3b. Those >9 years are less likely to receive IVIG altogether [215]B3b. The Kobayashi score, developed in Japanese children, does not reliably predict IVIG resistance or CAA in non-Asian populations, necessitating clinical vigilance in older children [217]B3b.
follows the same standard regimen, IVIG 2 g/kg as a single infusion and , but prompt recognition of incomplete KD in infants and older children is critical. Adjunctive corticosteroids (e.g., prednisolone 2 mg/kg/day for 15 days) may be considered in those predicted to be at high risk for IVIG resistance, though the benefit is best established in Japanese populations [32]A1b. All infants with KD should undergo echocardiography at baseline, 1-2 weeks, and 4-6 weeks, with particular attention to coronary z-scores [98]B2b.
Pregnancy
Kawasaki Disease in pregnancy is exceptionally rare, and no prospective data exist. Management should follow standard protocols with IVIG (safe during pregnancy) and low-dose aspirin. High-dose aspirin should be avoided in the third trimester because of the risk of premature ductus arteriosus closure. Multidisciplinary care involving maternal-fetal medicine and cardiology is recommended.
Elderly
Adult-onset KD is rare and may present with incomplete features, often mimicking other systemic vasculitides. A high index of suspicion is required. Treatment follows pediatric guidelines with IVIG and aspirin, but comorbidities such as coronary artery disease, , and renal impairment may influence the choice and dosing of anti-inflammatory therapy.
Immunocompromised
Limited data are available on KD in immunocompromised children. The diagnosis should be considered in any febrile patient with suggestive clinical features, regardless of immune status. Management follows standard care, with attention to potential drug interactions and infection risk. Whether immunosuppression modifies the risk of CAA is unknown.
Pearl: In infants under 1 year, the absence of classic KD features does not rule out the diagnosis, obtain an echocardiogram in any infant with unexplained prolonged fever, as the CAA rate approaches 40% in this age group [80]B2b.
Prevention, Screening & Surveillance
- ▸Early IVIG within 10 days of fever onset is the cornerstone of CAA prevention; delayed treatment increases CAA risk substantially [80].
- ▸High-risk patients identified by validated scores may benefit from adjunctive corticosteroids or ciclosporin to reduce CAA incidence, NNT of 5-6 [32][33].
- ▸Lifelong cardiac surveillance is mandatory for patients with CAA, with frequency determined by aneurysm size; stress imaging identifies inducible ischemia that predicts MACE [57][169][226].
Building on the special considerations for infants and adolescents, prevention of the most serious complication of Kawasaki disease (KD), coronary artery aneurysm (CAA), begins with early diagnosis and risk-stratified treatment. No primary preventive measure is known to reduce the risk of developing KD, as its etiology remains unidentified. Observational data from the pandemic, however, showed that infection control measures were associated with a 35% reduction in KD incidence in Japan [50]B3b, which then resurged after restrictions were lifted [49]B2b, supporting the hypothesis that one or more infectious triggers are involved [186]B2c.
Secondary Prevention: Preventing Coronary Sequelae
Timely administration of intravenous immunoglobulin (IVIG) within 10 days of fever onset is the cornerstone of CAA prevention. Delayed IVIG is strongly associated with higher CAA rates; in the UK and Ireland, children with CAA received IVIG at a median of 10 days compared with 7 days in those without CAA [80]B2b. Risk stratification for IVIG resistance identifies patients who may benefit from intensified primary therapy. Several scoring systems exist, though performance outside Japan is suboptimal [105]B2b. For predicted non-responders, adjunctive corticosteroids reduce CAA incidence. The RAISE trial demonstrated that addition of prednisolone (2 mg/kg/day for 15 days) to IVIG plus reduced CAA from 23% to 3% (risk difference 0.20, 95%; NNT = 5) [32]A1b. The KAICA trial showed that IVIG plus ciclosporin (5 mg/kg/day for 5 days) reduced CAA from 31% to 14% (risk ratio 0.46, 95%; NNT = 6) [33]A1b. Meta-analyses confirm that initial corticosteroid therapy lowers CAA risk (OR 0.32, 95%) and that the benefit is greatest when corticosteroids are given early, not as rescue therapy [140]A1a. For IVIG-resistant cases, (5 mg/kg single dose) achieves fever resolution within 48 hours in 77% of patients and is well tolerated [113]C4[220]C4. The ongoing KD-CAAP trial will determine whether unselected European children benefit from routine adjunctive corticosteroids [229]D5. Regarding aspirin dose, low-dose (3-5 mg/kg/day) is non-inferior to high-dose aspirin for preventing CAA when combined with IVIG, suggesting high-dose aspirin may not be necessary in the acute phase [222]B3b[224]D5. No benefit was found from adding high-dose aspirin to IVIG alone for CAA prevention [230]A1a.
Surveillance Schedule for Coronary Artery Abnormalities
All children with KD require baseline echocardiography at diagnosis and follow-up imaging to detect and monitor coronary involvement. The risk of myocardial infarction (MI) is highest within the first 2 years of acute KD, 81% of MIs occurred within 2 years, and 48% within 3 months [46]C4. Among patients with giant CAA (z score ≥10 or absolute diameter ≥8 mm), major adverse cardiovascular events (MACE) occurred in 21.7% over a median follow-up of 11 years, with 10-year MACE-free survival of 75% [169]B2b. Among those with CAA diameter ≥6 mm and body surface area <0.50 m², the 30-year cardiac event-free survival was approximately 60% [226]B2b. Stress perfusion cardiac magnetic resonance (spCMR) can identify inducible perfusion defects that predict future MACE (HR 4.2, 95%) and guide revascularization decisions [57]B3b.
| Risk Level | AHA Classification | Surveillance Modality | Frequency |
|---|---|---|---|
| No CAA | Level 1 | Echocardiogram, ECG | 2 weeks, 6-8 weeks, then at 1 year if normal; discharge from cardiology if persistently normal |
| Small-medium CAA (z score 2.5 to <10) | Level 2-3 | Echocardiogram, ECG, ± stress imaging | 2 weeks, 6-8 weeks, then every 6-12 months; consider stress test at 1 year |
| Large or giant CAA (z score ≥10 or absolute ≥8 mm) | Level 4-5 | Echocardiogram, spCMR or stress echo, ECG | 2 weeks, 6-8 weeks, then every 6 months; annual spCMR for ischemia surveillance; consider CT angiography |
| Surveillance should continue indefinitely for patients with persistent CAA, as late cardiac events can occur decades after KD [226]B2b[228]B2b. For those with regressed aneurysms, endothelial dysfunction may persist, and cardiovascular risk factor modification is recommended. |
Vaccine Considerations
Live virus vaccines ( - - , varicella, rotavirus) should be deferred for 11 months following IVIG administration due to potential interference with vaccine immune response, this is standard practice recommended by national immunization advisory bodies. The BCG vaccination site reaction (redness or crusting) is a useful diagnostic sign of KD in countries where BCG is routine, but BCG itself is not a preventive intervention [175]B3b[234]C4. Infliximab use in patients who received live viral vaccines within 90 days appears safe [233]C4. Rotavirus vaccination has not been associated with an increased risk of KD hospitalization [232]B2c. Regarding SARS-CoV-2 vaccination, rare cases of multisystem inflammatory syndrome following vaccination (MIS-V) have been reported in children, with features overlapping KD; however, the incidence is extremely low, and the benefits of vaccination far exceed this risk [221]C4. The European Medicines Agency and CDC recommend routine SARS-CoV-2 vaccination for children aged 6 months and older, including those with a history of KD, unless contraindicated for other reasons. Patient education should emphasize the importance of maintaining routine immunizations, recognizing early KD symptoms to avoid treatment delay, and adhering to long-term cardiac surveillance.
Pearl: Lifelong cardiac surveillance is mandatory for patients with CAA, with frequency determined by aneurysm size; stress imaging identifies inducible ischemia that predicts MACE [57]B3b[169]B2b[226]B2b.
References
- [1]
Abrams JY, Godfred-Cato SE, Oster ME et al.. “Multisystem Inflammatory Syndrome in Children Associated with Severe Acute Respiratory Syndrome Coronavirus 2: A Systematic Review.” The Journal of pediatrics (2020). PMID: 32768466 ↗
L4SR_OBSCited in: Definition, Classification & Nomenclature - [2]
Pinches H, Dobbins K, Cantrell S et al.. “Asymptomatic Kawasaki Disease in a 3-Month-Old Infant.” Pediatrics (2016). PMID: 27371760 ↗
L4CASE_REPORTCited in: Definition, Classification & Nomenclature, Clinical Presentation, Diagnosis & Workup, Complications - [3]
Wright H, Waddington C, Geddes J et al.. “Facial nerve palsy complicating Kawasaki disease.” Pediatrics (2008). PMID: 18678602 ↗
L4CASE_REPORTCited in: Definition, Classification & Nomenclature, Epidemiology, Etiology & Risk Factors, Diagnosis & Workup, Special Populations - [4]
Harrowell I, Webb R, Han DY et al.. “Increasing incidence of Kawasaki disease and associated coronary aneurysm in Aotearoa New Zealand: a retrospective cohort study.” Archives of disease in childhood (2025). PMID: 39627015 ↗
L2COHORTCited in: Definition, Classification & Nomenclature, Epidemiology, Etiology & Risk Factors, Special Populations - [5]
Kamidani S, Panagiotakopoulos L, Licata C et al.. “Kawasaki Disease Following the 13-valent Pneumococcal Conjugate Vaccine and Rotavirus Vaccines.” Pediatrics (2022). PMID: 36349537 ↗
L3OTHERCited in: Definition, Classification & Nomenclature, Diagnosis & Workup - [6]
Huang WC, Huang LM, Chang IS et al.. “Epidemiologic features of Kawasaki disease in Taiwan, 2003-2006.” Pediatrics (2009). PMID: 19237439 ↗
L2OTHERCited in: Definition, Classification & Nomenclature, Epidemiology, Etiology & Risk Factors, Special Populations - [7]
Day-Lewis M, Berbert L, Baker A et al.. “Updated Case Definition of MIS-C and Implications for Clinical Care.” Pediatrics (2024). PMID: 38204335 ↗
L2OTHERCited in: Definition, Classification & Nomenclature, Prevention, Screening & Surveillance - [8]
Cohen E, Sundel R. “Kawasaki Disease at 50 Years.” JAMA pediatrics (2016). PMID: 27668809 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification & Nomenclature, Epidemiology, Etiology & Risk Factors, Clinical Presentation, Diagnosis & Workup, Complications - [9]
Miura M, Kobayashi T, Kaneko T et al.. “Association of Severity of Coronary Artery Aneurysms in Patients With Kawasaki Disease and Risk of Later Coronary Events.” JAMA pediatrics (2018). PMID: 29507955 ↗
L2OTHERCited in: Definition, Classification & Nomenclature, Epidemiology, Etiology & Risk Factors, Diagnosis & Workup, Severity Grading, Staging & Risk Stratification, Prognosis & Natural History, Special Populations - [10]
Schöbi N, Sanchez C, Welzel T et al.. “Swissped-RECOVERY: masked independent adjudication for the interpretation of non-randomised treatment in a two-arm open-label randomised controlled trial (methylprednisolone vs immunoglobulins) in Paediatric Inflammatory Multisystem Syndrome Temporally Associated with SARS-CoV-2 (PIMS-TS) involving 10 secondary and tertiary paediatric hospitals in Switzerland.” BMJ open (2024). PMID: 38670610 ↗
L1RCTCited in: Definition, Classification & Nomenclature, Long-term & Definitive Management - [11]
Jiao F, Pan Y, Du Z et al.. “Guideline for the diagnosis and treatment of incomplete Kawasaki disease in children in China.” BMC pediatrics (2024). PMID: 39060924 ↗
L1GUIDELINECited in: Definition, Classification & Nomenclature - [12]
Padilla LA, Collins JL, Idigo AJ et al.. “Kawasaki Disease and Clinical Outcome Disparities Among Black Children.” The Journal of pediatrics (2020). PMID: 32980379 ↗
L2OTHERCited in: Definition, Classification & Nomenclature, Epidemiology, Etiology & Risk Factors, Diagnosis & Workup, Complications, Prognosis & Natural History - [13]
Lo J, Gauvreau K, Baker AL et al.. “Multiple Emergency Department Visits for a Diagnosis of Kawasaki Disease: An Examination of Risk Factors and Outcomes.” The Journal of pediatrics (2021). PMID: 33453202 ↗
L2OTHERCited in: Definition, Classification & Nomenclature - [14]
Hao S, Jin B, Tan Z et al.. “A Classification Tool for Differentiation of Kawasaki Disease from Other Febrile Illnesses.” The Journal of pediatrics (2016). PMID: 27344221 ↗
L3OTHERCited in: Definition, Classification & Nomenclature - [15]
Tsuda E, Hashimoto S. “Time Course of Coronary Artery Aneurysms in Kawasaki Disease.” The Journal of pediatrics (2020). PMID: 33301786 ↗
L4OTHERCited in: Definition, Classification & Nomenclature - [16]
Gee P, Burgner D, Gee W et al.. “Rising Kawasaki disease incidence in New Zealand: analysis of national population incidence and outcomes 2000-2017.” Archives of disease in childhood (2023). PMID: 37553209 ↗
L2OTHERCited in: Definition, Classification & Nomenclature, Epidemiology, Etiology & Risk Factors, Growth, Development & Nutrition Impact, Complications, Prognosis & Natural History, Special Populations, Prevention, Screening & Surveillance - [17]
Ma M, Aoki Y, Kitazawa K. “Atypical Cat Scratch Disease With Splenic Lesion Mimicking Kawasaki Disease in a Healthy 5-Year-old Girl.” The Pediatric infectious disease journal (2023). PMID: 37922474 ↗
L4CASE_REPORTCited in: Definition, Classification & Nomenclature, Diagnosis & Workup, History and Evolution of Treatment - [18]
Karalexi MA, Mitrogiorgou M, Atsali E et al.. “Murine Typhus Mimicking Kawasaki Disease in a Preadolescent Girl.” The Pediatric infectious disease journal (2018). PMID: 29742650 ↗
L4CASE_REPORTCited in: Definition, Classification & Nomenclature - [19]
Kim H, Jang H, Lee W et al.. “Association between long-term PM2.5 exposure and risk of Kawasaki disease in children: A nationwide longitudinal cohort study.” Environmental research (2023). PMID: 38072109 ↗
L2COHORTCited in: Definition, Classification & Nomenclature - [20]
Chen X, Ding B, Shen Z et al.. “The predictive value of the ratio of multi-dimensional inflammatory biomarkers in pediatric diseases from the perspective of pro-inflammatory/anti-inflammatory balance: a systematic review.” Translational pediatrics (2026). PMID: 42292611 ↗
L5SR_OBSCited in: Definition, Classification & Nomenclature, Diagnosis & Workup, Severity Grading, Staging & Risk Stratification - [21]
Maddox RA, Person MK, Kennedy JL et al.. “Kawasaki Disease and Kawasaki Disease Shock Syndrome Hospitalization Rates in the United States, 2006-2018.” The Pediatric infectious disease journal (2021). PMID: 33264213 ↗
L2OTHERCited in: Definition, Classification & Nomenclature, Special Populations, Prevention, Screening & Surveillance - [22]
Uehara R, Belay ED, Maddox RA et al.. “Analysis of potential risk factors associated with nonresponse to initial intravenous immunoglobulin treatment among Kawasaki disease patients in Japan.” The Pediatric infectious disease journal (2008). PMID: 18174868 ↗
L2OTHERCited in: Definition, Classification & Nomenclature - [23]
Clark DE, Denby KJ, Kaufman LM et al.. “Predictors of Intravenous Immunoglobulin Nonresponse and Racial Disparities in Kawasaki Disease.” The Pediatric infectious disease journal (2018). PMID: 29570178 ↗
L2OTHERCited in: Definition, Classification & Nomenclature, Diagnosis & Workup, Severity Grading, Staging & Risk Stratification, Complications - [24]
Lei WT, Lin CY, Kao YH et al.. “The risk of hospitalization for respiratory tract infection (RTI) in children who are treated with high-dose IVIG in Kawasaki Disease: a nationwide population-based matched cohort study.” PeerJ (2018). PMID: 29593942 ↗
L2COHORTCited in: Pathophysiology & Developmental Mechanism - [25]
Vogel T, Kitcharoensakkul M, Fotis L et al.. “The heart and pediatric rheumatology.” Rheumatic diseases clinics of North America (2014). PMID: 24268010 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Developmental Mechanism - [26]
Candelino M, Tagi VM, Chiarelli F. “Cardiovascular risk in children: a burden for future generations.” Italian journal of pediatrics (2022). PMID: 35410281 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Developmental Mechanism - [27]
Jeudy J, White CS, Kligerman SJ et al.. “Spectrum of Coronary Artery Aneurysms: From the Radiologic Pathology Archives.” Radiographics : a review publication of the Radiological Society of North America, Inc (2018). PMID: 29320324 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Developmental Mechanism - [28]
Dorfman AL, Geva T, Samyn MM et al.. “SCMR expert consensus statement for cardiovascular magnetic resonance of acquired and non-structural pediatric heart disease.” Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance (2022). PMID: 35864534 ↗
L1REVIEW_NARRATIVECited in: Pathophysiology & Developmental Mechanism - [29]
Woźniak P, Iwańczyk S, Błaszyk M et al.. “Coronary Artery Aneurysm or Ectasia as a Form of Coronary Artery Remodeling: Etiology, Pathogenesis, Diagnostics, Complications, and Treatment.” Biomedicines (2024). PMID: 39335497 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Developmental Mechanism - [30]
Abou Sherif S, Ozden Tok O, Taşköylü Ö et al.. “Coronary Artery Aneurysms: A Review of the Epidemiology, Pathophysiology, Diagnosis, and Treatment.” Frontiers in cardiovascular medicine (2017). PMID: 28529940 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Developmental Mechanism - [31]
Lin S, He Y, He L et al.. “Randomized Trial of Adjunctive Prednisolone for Kawasaki Disease.” The New England journal of medicine (2026). PMID: 41985133 ↗
L1RCTCited in: Epidemiology, Etiology & Risk Factors, Acute & Emergency Management: Neonatal Resuscitation & Pediatric Stabilization, Long-term & Definitive Management, History and Evolution of Treatment, Prognosis & Natural History, Special Populations - [32]
Kobayashi T, Saji T, Otani T et al.. “Efficacy of immunoglobulin plus prednisolone for prevention of coronary artery abnormalities in severe Kawasaki disease (RAISE study): a randomised, open-label, blinded-endpoints trial.” Lancet (London, England) (2012). PMID: 22405251 ↗
L1RCTCited in: Epidemiology, Etiology & Risk Factors, Acute & Emergency Management: Neonatal Resuscitation & Pediatric Stabilization, Long-term & Definitive Management, History and Evolution of Treatment, Special Populations, Prevention, Screening & Surveillance - [33]
Hamada H, Suzuki H, Onouchi Y et al.. “Efficacy of primary treatment with immunoglobulin plus ciclosporin for prevention of coronary artery abnormalities in patients with Kawasaki disease predicted to be at increased risk of non-response to intravenous immunoglobulin (KAICA): a randomised controlled, open-label, blinded-endpoints, phase 3 trial.” Lancet (London, England) (2019). PMID: 30853151 ↗
L1RCTCited in: Epidemiology, Etiology & Risk Factors, Acute & Emergency Management: Neonatal Resuscitation & Pediatric Stabilization, Long-term & Definitive Management, History and Evolution of Treatment, Growth, Development & Nutrition Impact, Prevention, Screening & Surveillance - [34]
Sleeper LA, Minich LL, McCrindle BM et al.. “Evaluation of Kawasaki disease risk-scoring systems for intravenous immunoglobulin resistance.” The Journal of pediatrics (2010). PMID: 21168857 ↗
L2RCTCited in: Epidemiology, Etiology & Risk Factors, Acute & Emergency Management: Neonatal Resuscitation & Pediatric Stabilization, Long-term & Definitive Management, History and Evolution of Treatment - [35]
Dominguez SR, Friedman K, Seewald R et al.. “Kawasaki disease in a pediatric intensive care unit: a case-control study.” Pediatrics (2008). PMID: 18809597 ↗
L3CASE_CONTROLCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup, Severity Grading, Staging & Risk Stratification, Growth, Development & Nutrition Impact, Special Populations - [36]
Hwang JY, Lee KY, Rhim JW et al.. “Assessment of intravenous immunoglobulin non-responders in Kawasaki disease.” Archives of disease in childhood (2010). PMID: 20551193 ↗
L2TRIAL_NONRANDOMCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup, Severity Grading, Staging & Risk Stratification - [37]
Verdoni L, Mazza A, Gervasoni A et al.. “An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study.” Lancet (London, England) (2020). PMID: 32410760 ↗
L2COHORTCited in: Epidemiology, Etiology & Risk Factors, Clinical Presentation - [38]
Chiang MH, Liu HE, Wang JL. “Low-dose or no aspirin administration in acute-phase Kawasaki disease: a meta-analysis and systematic review.” Archives of disease in childhood (2020). PMID: 33172886 ↗
L2SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Long-term & Definitive Management, Special Populations - [39]
Saundankar J, Yim D, Itotoh B et al.. “The epidemiology and clinical features of Kawasaki disease in Australia.” Pediatrics (2014). PMID: 24685950 ↗
L2OTHERCited in: Epidemiology, Etiology & Risk Factors, Clinical Presentation, Prevention, Screening & Surveillance - [40]
Zhao QM, Chu C, Wu L et al.. “Systemic Artery Aneurysms and Kawasaki Disease.” Pediatrics (2019). PMID: 31732547 ↗
L2OTHERCited in: Epidemiology, Etiology & Risk Factors, Special Populations - [41]
Turnier JL, Anderson MS, Heizer HR et al.. “Concurrent Respiratory Viruses and Kawasaki Disease.” Pediatrics (2015). PMID: 26304824 ↗
L3OTHERCited in: Epidemiology, Etiology & Risk Factors, Clinical Presentation, Diagnosis & Workup, Special Populations - [42]
Molloy MJ, Auger KA, Hall M et al.. “Epidemiology and Severity of Illness of MIS-C and Kawasaki Disease During the COVID-19 Pandemic.” Pediatrics (2023). PMID: 37791428 ↗
L3OTHERCited in: Epidemiology, Etiology & Risk Factors, Severity Grading, Staging & Risk Stratification, Complications, Prognosis & Natural History - [43]
Weng KP, Cheng-Chung Wei J, Hung YM et al.. “Enterovirus Infection and Subsequent Risk of Kawasaki Disease: A Population-based Cohort Study.” The Pediatric infectious disease journal (2018). PMID: 28834956 ↗
L3COHORTCited in: Epidemiology, Etiology & Risk Factors, Prognosis & Natural History, Special Populations - [44]
Ae R, Makino N, Kuwabara M et al.. “Incidence of Kawasaki Disease Before and After the COVID-19 Pandemic in Japan: Results of the 26th Nationwide Survey, 2019 to 2020.” JAMA pediatrics (2022). PMID: 36251290 ↗
L3OTHERCited in: Epidemiology, Etiology & Risk Factors - [45]
Bailey LC, Razzaghi H, Burrows EK et al.. “Assessment of 135 794 Pediatric Patients Tested for Severe Acute Respiratory Syndrome Coronavirus 2 Across the United States.” JAMA pediatrics (2021). PMID: 33226415 ↗
L3OTHERCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup, Special Populations - [46]
Ghelani SJ, Baker AL, Friedman K et al.. “Myocardial Infarction in Kawasaki Disease.” The Journal of pediatrics (2025). PMID: 40368243 ↗
L4OTHERCited in: Epidemiology, Etiology & Risk Factors, Clinical Presentation, History and Evolution of Treatment, Complications, Special Populations, Prevention, Screening & Surveillance - [47]
Baker AL, Vanderpluym C, Gauvreau KA et al.. “Safety and Efficacy of Warfarin Therapy in Kawasaki Disease.” The Journal of pediatrics (2017). PMID: 28552449 ↗
L4OTHERCited in: Epidemiology, Etiology & Risk Factors, History and Evolution of Treatment, Complications, Special Populations - [48]
Zeft AS, Burns JC, Yeung RS et al.. “Kawasaki Disease and Exposure to Fine Particulate Air Pollution.” The Journal of pediatrics (2016). PMID: 27496266 ↗
L3OTHERCited in: Epidemiology, Etiology & Risk Factors - [49]
Nakata F, Matsubara K, Hamahata K et al.. “Resurgence of Kawasaki Disease Following Relaxation of Coronavirus Disease 2019 Pandemic Restrictions in Japan.” The Journal of pediatrics (2024). PMID: 39181319 ↗
L2OTHERCited in: Epidemiology, Etiology & Risk Factors, Special Populations, Prevention, Screening & Surveillance - [50]
Ae R, Shibata Y, Kosami K et al.. “Kawasaki Disease and Pediatric Infectious Diseases During the Coronavirus Disease 2019 Pandemic.” The Journal of pediatrics (2021). PMID: 34324881 ↗
L3OTHERCited in: Epidemiology, Etiology & Risk Factors, Special Populations, Prevention, Screening & Surveillance - [51]
Singh S, Vignesh P, Burgner D. “The epidemiology of Kawasaki disease: a global update.” Archives of disease in childhood (2015). PMID: 26111818 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors - [52]
Takaki S, Kobayashi T, Kuwabara M et al.. “Coronary artery complications in patients with Kawasaki disease who successfully responded to the standard initial IVIG treatment.” Archives of disease in childhood (2024). PMID: 39227142 ↗
L2OTHERCited in: Epidemiology, Etiology & Risk Factors, Growth, Development & Nutrition Impact, Complications, Prognosis & Natural History, Special Populations - [53]
Sudo D, Makino N, Nakamura Y. “Recurrent Kawasaki disease and cardiac complications: nationwide surveys in Japan.” Archives of disease in childhood (2020). PMID: 32107252 ↗
L2OTHERCited in: Epidemiology, Etiology & Risk Factors, History and Evolution of Treatment, Complications, Special Populations - [54]
Wen J, Wu Y, Huang P et al.. “Higher IVIG resistance in Kawasaki disease patients treated early after fever onset: a single-center retrospective study of 2,988 cases.” European journal of pediatrics (2026). PMID: 42223674 ↗
L3COHORTCited in: Epidemiology, Etiology & Risk Factors, Clinical Presentation, Severity Grading, Staging & Risk Stratification, Special Populations - [55]
Li X, Zhou Z, Fan J et al.. “Predicting coronary artery lesions in patients with Kawasaki disease in China using a machine-learning algorithm: a retrospective cohort study.” Frontiers in immunology (2026). PMID: 42099647 ↗
L3COHORTCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup, Special Populations - [56]
Bie W, Guan Y, Du Q et al.. “Retrospective study: clinical analysis of Kawasaki disease complicated with macrophage activation syndrome.” Italian journal of pediatrics (2026). PMID: 41864993 ↗
L3COHORTCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup, Complications, Special Populations - [57]
Kiener AJ, Sexson Tejtel SK, Liou A et al.. “Prognostic value of stress perfusion cardiac magnetic resonance imaging in Kawasaki disease with coronary artery aneurysms: A 10-year retrospective cohort study.” Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance (2026). PMID: 41638925 ↗
L3COHORTCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup, Special Populations, Prevention, Screening & Surveillance - [58]
Wang HY, Chen S, Zhang C et al.. “IL-10 and IL-2R as combined predictors of intravenous immunoglobulin resistance in Kawasaki disease: a retrospective cohort study.” Frontiers in immunology (2025). PMID: 41415281 ↗
L3COHORTCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup, Special Populations - [59]
Du Q, Zhang X, Sun H et al.. “Value of the neutrophil percentage-to-albumin ratio in predicting intravenous Immunoglobulin resistance in Kawasaki disease: a retrospective cohort study.” Italian journal of pediatrics (2025). PMID: 41310824 ↗
L3COHORTCited in: Epidemiology, Etiology & Risk Factors - [60]
Broderick C, Kobayashi S, Suto M et al.. “Intravenous immunoglobulin for the treatment of Kawasaki disease.” The Cochrane database of systematic reviews (2023). PMID: 36695415 ↗
L1SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Complications, Prognosis & Natural History - [61]
Wardle AJ, Connolly GM, Seager MJ et al.. “Corticosteroids for the treatment of Kawasaki disease in children.” The Cochrane database of systematic reviews (2017). PMID: 28129459 ↗
L1SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Complications, Prognosis & Natural History, Special Populations - [62]
Green J, Wardle AJ, Tulloh RM. “Corticosteroids for the treatment of Kawasaki disease in children.” The Cochrane database of systematic reviews (2022). PMID: 35622534 ↗
L1SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Complications, Prognosis & Natural History - [63]
Yamaji N, da Silva Lopes K, Shoda T et al.. “TNF-α blockers for the treatment of Kawasaki disease in children.” The Cochrane database of systematic reviews (2019). PMID: 31425625 ↗
L1SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Special Populations - [64]
Godfred-Cato S, Abrams JY, Balachandran N et al.. “Distinguishing Multisystem Inflammatory Syndrome in Children From COVID-19, Kawasaki Disease and Toxic Shock Syndrome.” The Pediatric infectious disease journal (2022). PMID: 35093995 ↗
L2OTHERCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup, Complications, Special Populations - [65]
Doan NH, Sivilay N, Shimizu C et al.. “Incidence and Severity of Kawasaki Disease Among Vietnamese Children.” The Pediatric infectious disease journal (2022). PMID: 36223235 ↗
L3OTHERCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup, Severity Grading, Staging & Risk Stratification, Prognosis & Natural History - [66]
Rand KH, Bhaduri-McIntosh S, Gurka MJ et al.. “Is Kawasaki Disease Caused by a Respiratory Virus?” The Pediatric infectious disease journal (2023). PMID: 37171979 ↗
L2OTHERCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup, History and Evolution of Treatment - [67]
Lin YH, Lin CH, Lin MC. “Declining Incidence of Kawasaki Disease During the COVID-19 Pandemic: A Time Series Analysis.” The Pediatric infectious disease journal (2024). PMID: 38916916 ↗
L2OTHERCited in: Epidemiology, Etiology & Risk Factors - [68]
Kim GB, Eun LY, Han JW et al.. “Epidemiology of Kawasaki Disease in South Korea: A Nationwide Survey 2015-2017.” The Pediatric infectious disease journal (2020). PMID: 33075217 ↗
L2OTHERCited in: Epidemiology, Etiology & Risk Factors, Complications - [69]
Kim GB, Park S, Eun LY et al.. “Epidemiology and Clinical Features of Kawasaki Disease in South Korea, 2012-2014.” The Pediatric infectious disease journal (2017). PMID: 27997519 ↗
L2OTHERCited in: Epidemiology, Etiology & Risk Factors, Clinical Presentation, Diagnosis & Workup, Complications - [70]
Colomba C, La Placa S, Saporito L et al.. “Intestinal Involvement in Kawasaki Disease.” The Journal of pediatrics (2018). PMID: 30029859 ↗
L4SR_OBSCited in: Clinical Presentation, Diagnosis & Workup, Complications, Prognosis & Natural History, Special Populations - [71]
Tissandier C, Lang M, Lusson JR et al.. “Kawasaki shock syndrome complicating a recurrence of Kawasaki disease.” Pediatrics (2014). PMID: 25384485 ↗
L4CASE_REPORTCited in: Clinical Presentation, Diagnosis & Workup - [72]
Thors VS, Vastert SJ, Wulffraat N et al.. “Periodic fever in MVK deficiency: a patient initially diagnosed with incomplete Kawasaki disease.” Pediatrics (2014). PMID: 24470648 ↗
L4CASE_REPORTCited in: Clinical Presentation - [73]
Bautista-Rodriguez C, Sanchez-de-Toledo J, Clark BC et al.. “Multisystem Inflammatory Syndrome in Children: An International Survey.” Pediatrics (2020). PMID: 33234669 ↗
L4OTHERCited in: Clinical Presentation, Prognosis & Natural History - [74]
Kaushik A, Gupta S, Sood M et al.. “A Systematic Review of Multisystem Inflammatory Syndrome in Children Associated With SARS-CoV-2 Infection.” The Pediatric infectious disease journal (2020). PMID: 32925547 ↗
L4SR_OBSCited in: Clinical Presentation, Prognosis & Natural History, Special Populations - [75]
Avcin T, Tse SM, Schneider R et al.. “Macrophage activation syndrome as the presenting manifestation of rheumatic diseases in childhood.” The Journal of pediatrics (2006). PMID: 16737887 ↗
L4CASE_REPORTCited in: Clinical Presentation - [76]
Wright VJ, Herberg JA, Kaforou M et al.. “Diagnosis of Kawasaki Disease Using a Minimal Whole-Blood Gene Expression Signature.” JAMA pediatrics (2018). PMID: 30083721 ↗
L3OTHERCited in: Clinical Presentation, Diagnosis & Workup, Special Populations - [77]
Narayan HK, Lizcano A, Lam-Hine T et al.. “Clinical Presentation and Outcomes of Kawasaki Disease in Children from Latin America: A Multicenter Observational Study from the REKAMLATINA Network.” The Journal of pediatrics (2023). PMID: 36775190 ↗
L2OTHERCited in: Clinical Presentation - [78]
Power A, Runeckles K, Manlhiot C et al.. “Kawasaki Disease Shock Syndrome Versus Septic Shock: Early Differentiating Features Despite Overlapping Clinical Profiles.” The Journal of pediatrics (2020). PMID: 33290811 ↗
L3OTHERCited in: Clinical Presentation, Severity Grading, Staging & Risk Stratification - [79]
Burns JC, DeHaan LL, Shimizu C et al.. “Temporal Clusters of Kawasaki Disease Cases Share Distinct Phenotypes That Suggest Response to Diverse Triggers.” The Journal of pediatrics (2020). PMID: 32976897 ↗
L3OTHERCited in: Clinical Presentation - [80]
Tulloh RMR, Mayon-White R, Harnden A et al.. “Kawasaki disease: a prospective population survey in the UK and Ireland from 2013 to 2015.” Archives of disease in childhood (2018). PMID: 30104394 ↗
L2OTHERCited in: Clinical Presentation, Complications, Prognosis & Natural History, Special Populations, Prevention, Screening & Surveillance - [81]
Hao S, Ling XB, Kanegaye JT et al.. “Multicentre validation of a computer-based tool for differentiation of acute Kawasaki disease from clinically similar febrile illnesses.” Archives of disease in childhood (2020). PMID: 32139365 ↗
L2OTHERCited in: Clinical Presentation, Diagnosis & Workup - [82]
Eladawy M, Dominguez SR, Anderson MS et al.. “Abnormal liver panel in acute kawasaki disease.” The Pediatric infectious disease journal (2011). PMID: 20861758 ↗
L2OTHERCited in: Clinical Presentation, Growth, Development & Nutrition Impact - [83]
Kaneta K, Malhotra S, Szmuszkovicz J et al.. “Expanding the Differential for Alternative Diagnoses in the Workup of Multisystem Inflammatory Syndrome in Children.” The Pediatric infectious disease journal (2023). PMID: 36917023 ↗
L2OTHERCited in: Clinical Presentation - [84]
Tacke CE, Breunis WB, Pereira RR et al.. “Five years of Kawasaki disease in the Netherlands: a national surveillance study.” The Pediatric infectious disease journal (2014). PMID: 24463809 ↗
L2OTHERCited in: Clinical Presentation, Growth, Development & Nutrition Impact, Prevention, Screening & Surveillance - [85]
Sung RY, Ng YM, Choi KC et al.. “Lack of association of cervical lymphadenopathy and coronary artery complications in Kawasaki disease.” The Pediatric infectious disease journal (2006). PMID: 16732150 ↗
L2OTHERCited in: Clinical Presentation - [86]
Duan Y, Chen A, Cheng X. “A retrospective cohort study using machine learning to predict coronary artery lesions in children with Kawasaki disease.” BMC pediatrics (2025). PMID: 40745593 ↗
L2COHORTCited in: Clinical Presentation - [87]
Zhang Y, Yuan X, Yang X et al.. “Longitudinal management and novel pharmacological interactions in a patient with HeFH, 21-OHD, and kawasaki disease: a 6-year clinical follow-up.” Frontiers in endocrinology (2026). PMID: 42109749 ↗
L4CASE_REPORTCited in: Clinical Presentation, Complications - [88]
Xue B, Luo M, Wen Y et al.. “Multidisciplinary management of refractory Kawasaki disease with bilateral giant coronary artery aneurysms and latent tuberculosis infection: a case report focusing on immune-coagulation-infection crosstalk.” Frontiers in immunology (2026). PMID: 41890727 ↗
L4CASE_REPORTCited in: Clinical Presentation - [89]
Chen H, Xia W, Peng Y et al.. “A case report of severe Mycoplasma pneumoniae pneumonia complicated by plastic bronchitis and Kawasaki disease.” BMC infectious diseases (2025). PMID: 41291456 ↗
L4CASE_REPORTCited in: Clinical Presentation, Complications - [90]
Amendolea A, Gaeta G, Avino G. “The role of thoracic ultrasound in a rare combination of lung abscess and congenital pulmonary airway malformation (CPAM): case report and brief review.” Italian journal of pediatrics (2025). PMID: 41131622 ↗
L4CASE_REPORTCited in: Clinical Presentation - [91]
Lee JJY, Lin E, Widdifield J et al.. “The Long-term Cardiac and Noncardiac Prognosis of Kawasaki Disease: A Systematic Review.” Pediatrics (2022). PMID: 35118494 ↗
L2SR_OBSCited in: Diagnosis & Workup, Complications, Prognosis & Natural History - [92]
Yang J, Jain S, Capparelli EV et al.. “Anakinra Treatment in Patients with Acute Kawasaki Disease with Coronary Artery Aneurysms: A Phase I/IIa Trial.” The Journal of pediatrics (2021). PMID: 34953816 ↗
L2TRIAL_NONRANDOMCited in: Diagnosis & Workup - [93]
Watanabe Y, Ikeda H, Watanabe T. “Differences in the Clinical Characteristics of Kawasaki Disease Between Older and Younger Children (2015-2019): A Single-Center, Retrospective Study.” The Journal of pediatrics (2022). PMID: 36208665 ↗
L2COHORTCited in: Diagnosis & Workup - [94]
Kim SY, Shin JS, Jang MS et al.. “Clinical characteristics of patients with recurrent Kawasaki disease: a nationwide cohort study of 19 456 patients with minimum 3-year follow up.” Archives of disease in childhood (2022). PMID: 36549869 ↗
L2COHORTCited in: Diagnosis & Workup, Complications - [95]
Gámez-González LB, Murata C, García-Silva J et al.. “Macrophage Activation Syndrome in MIS-C.” Pediatrics (2024). PMID: 39539128 ↗
L2OTHERCited in: Diagnosis & Workup, History and Evolution of Treatment, Complications, Prognosis & Natural History, Special Populations - [96]
Miselli F, Mastrolia MV, Simonini G et al.. “Splenomegaly in Kawasaki Disease: A Pitfall in Diagnosis.” The Journal of pediatrics (2023). PMID: 36813130 ↗
L4CASE_REPORTCited in: Diagnosis & Workup - [97]
Michelson KA, Rees CA, Florin TA et al.. “Emergency Department Volume and Delayed Diagnosis of Serious Pediatric Conditions.” JAMA pediatrics (2024). PMID: 38345811 ↗
L2OTHERCited in: Diagnosis & Workup, Complications, Prognosis & Natural History - [98]
de Ferranti SD, Gauvreau K, Friedman KG et al.. “Association of Initially Normal Coronary Arteries With Normal Findings on Follow-up Echocardiography in Patients With Kawasaki Disease.” JAMA pediatrics (2018). PMID: 30285057 ↗
L2OTHERCited in: Diagnosis & Workup, Special Populations - [99]
Johnson SC, Chew M, Williams DC et al.. “Assessing Health Care Utilization and Compliance in Kawasaki Disease.” The Journal of pediatrics (2021). PMID: 33753117 ↗
L2OTHERCited in: Diagnosis & Workup, Complications, Prognosis & Natural History, Special Populations - [100]
Skochko SM, Jain S, Sun X et al.. “Kawasaki Disease Outcomes and Response to Therapy in a Multiethnic Community: A 10-Year Experience.” The Journal of pediatrics (2018). PMID: 30268398 ↗
L2OTHERCited in: Diagnosis & Workup, History and Evolution of Treatment, Prognosis & Natural History - [101]
Ae R, Makino N, Kosami K et al.. “Epidemiology, Treatments, and Cardiac Complications in Patients with Kawasaki Disease: The Nationwide Survey in Japan, 2017-2018.” The Journal of pediatrics (2020). PMID: 32454114 ↗
L4OTHERCited in: Diagnosis & Workup - [102]
Procyk G, Rosół N, Lamparski Ł et al.. “The role of microRNAs in Kawasaki disease: a systematic review.” European journal of pediatrics (2026). PMID: 41709025 ↗
L2SR_OBSCited in: Diagnosis & Workup - [103]
Miyata K, Bainto EV, Sun X et al.. “Infliximab for intensification of primary therapy for patients with Kawasaki disease and coronary artery aneurysms at diagnosis.” Archives of disease in childhood (2023). PMID: 37258054 ↗
L2OTHERCited in: Diagnosis & Workup, Prognosis & Natural History - [104]
Nijman RG, Tan CD, Hagedoorn NN et al.. “Are children with prolonged fever at a higher risk for serious illness? A prospective observational study.” Archives of disease in childhood (2023). PMID: 37185174 ↗
L2OTHERCited in: Diagnosis & Workup - [105]
Yang S, Song R, Zhang J et al.. “Predictive tool for intravenous immunoglobulin resistance of Kawasaki disease in Beijing.” Archives of disease in childhood (2018). PMID: 30026252 ↗
L2OTHERCited in: Diagnosis & Workup, Severity Grading, Staging & Risk Stratification, Prevention, Screening & Surveillance - [106]
Friedman KG, Gauvreau K, Baker A et al.. “Primary adjunctive corticosteroid therapy is associated with improved outcomes for patients with Kawasaki disease with coronary artery aneurysms at diagnosis.” Archives of disease in childhood (2020). PMID: 32943389 ↗
L2OTHERCited in: Diagnosis & Workup, History and Evolution of Treatment - [107]
Singh S, Aulakh R, Bhalla AK et al.. “Is Kawasaki disease incidence rising in Chandigarh, North India?” Archives of disease in childhood (2010). PMID: 20923951 ↗
L4OTHERCited in: Diagnosis & Workup - [108]
Mastrolia MV, Pandiarajan V, Cattalini M et al.. “Predictive value for intravenous immunoglobulin resistance of Kobayashi and Kawanet scores in 722 children with Kawasaki disease across diverse ethnic backgrounds (KIWI study): an international cohort study.” EClinicalMedicine (2026). PMID: 41809203 ↗
L2COHORTCited in: Diagnosis & Workup - [109]
Baumer JH, Love SJ, Gupta A et al.. “Salicylate for the treatment of Kawasaki disease in children.” The Cochrane database of systematic reviews (2006). PMID: 17054199 ↗
L1SR_OBSCited in: Diagnosis & Workup - [110]
Sakai-Bizmark R, Estevez D, Wu F et al.. “Kawasaki Disease Before and During the COVID-19 Pandemic: A Nationwide Population-based Study in the United States.” The Pediatric infectious disease journal (2023). PMID: 37725798 ↗
L2OTHERCited in: Diagnosis & Workup, Special Populations - [111]
Tremoulet AH, Jain S, Chandrasekar D et al.. “Evolution of laboratory values in patients with Kawasaki disease.” The Pediatric infectious disease journal (2011). PMID: 21817952 ↗
L4OTHERCited in: Diagnosis & Workup, History and Evolution of Treatment - [112]
Menchaca-Aguayo H, Alpízar-Rodríguez D, León-Rodríguez C et al.. “Therapeutic plasma exchange in autoimmune diseases: a retrospective study in a tertiary pediatric hospital in Mexico.” Frontiers in pediatrics (2025). PMID: 41210231 ↗
L4COHORTCited in: Diagnosis & Workup - [113]
Miura M, Kobayashi T, Igarashi T et al.. “Real-world Safety and Effectiveness of Infliximab in Pediatric Patients With Acute Kawasaki Disease: A Postmarketing Surveillance in Japan (SAKURA Study).” The Pediatric infectious disease journal (2020). PMID: 31815838 ↗
L4TRIAL_NONRANDOMCited in: Severity Grading, Staging & Risk Stratification, Prevention, Screening & Surveillance - [114]
Masuda H, Kobayashi T, Hachiya A et al.. “Infliximab for the Treatment of Refractory Kawasaki Disease: A Nationwide Survey in Japan.” The Journal of pediatrics (2017). PMID: 29224935 ↗
L4OTHERCited in: Severity Grading, Staging & Risk Stratification - [115]
Abrams JY, Belay ED, Uehara R et al.. “Cardiac Complications, Earlier Treatment, and Initial Disease Severity in Kawasaki Disease.” The Journal of pediatrics (2017). PMID: 28619520 ↗
L2OTHERCited in: Severity Grading, Staging & Risk Stratification - [116]
Iio K, Morikawa Y, Miyata K et al.. “Risk Factors of Coronary Artery Aneurysms in Kawasaki Disease with a Low Risk of Intravenous Immunoglobulin Resistance: An Analysis of Post RAISE.” The Journal of pediatrics (2021). PMID: 34461064 ↗
L2OTHERCited in: Severity Grading, Staging & Risk Stratification - [117]
Tsuda E, Yashiro M, Nakamura Y. “Cardiac Valvular Lesions due to Kawasaki Disease: A Japanese Nationwide Survey.” The Journal of pediatrics (2020). PMID: 32089190 ↗
L4OTHERCited in: Severity Grading, Staging & Risk Stratification, Growth, Development & Nutrition Impact - [118]
Chih WL, Wu PY, Sun LC et al.. “Progressive Coronary Dilatation Predicts Worse Outcome in Kawasaki Disease.” The Journal of pediatrics (2016). PMID: 26852179 ↗
L2OTHERCited in: Severity Grading, Staging & Risk Stratification, Prognosis & Natural History - [119]
Schwartzenburg E, Strelow J, Chowdhury SM. “Comparison of Risk-Scoring Systems in Predicting Kawasaki Disease Associated Coronary Artery Dilation in a North American Cohort.” Pediatric cardiology (2024). PMID: 39097853 ↗
L2RCTCited in: Severity Grading, Staging & Risk Stratification - [120]
Cameron SA, Carr M, Pahl E et al.. “Coronary artery aneurysms are more severe in infants than in older children with Kawasaki disease.” Archives of disease in childhood (2018). PMID: 30413485 ↗
L2OTHERCited in: Severity Grading, Staging & Risk Stratification - [121]
Robert AC, Parmentier AL, Schulze O et al.. “Studying Clinical, Biologic and Echocardiography Criteria to Predict a Resistant Kawasaki Disease in Children.” The Pediatric infectious disease journal (2021). PMID: 34250971 ↗
L2OTHERCited in: Severity Grading, Staging & Risk Stratification - [122]
Almeida FJ, Jarovsky D, Almeida Farias CG et al.. “High Fatality Rates in Pediatric Multisystem Inflammatory Syndrome: A Multicenter Experience From the Epicenter of Brazil's Coronavirus Pandemic.” The Pediatric infectious disease journal (2023). PMID: 37991363 ↗
L4OTHERCited in: Severity Grading, Staging & Risk Stratification - [123]
Kobayashi T, Inoue Y, Otani T et al.. “Risk stratification in the decision to include prednisolone with intravenous immunoglobulin in primary therapy of Kawasaki disease.” The Pediatric infectious disease journal (2009). PMID: 19504733 ↗
L2OTHERCited in: Severity Grading, Staging & Risk Stratification - [124]
Bodnarchuk-Sokhatska N, Pavlyshyn H, Kozak K et al.. “The clinical manifestation and diagnostic features of Kawasaki-like phenotypes in pediatric multisystem inflammatory syndrome: a comparative retrospective study in Ukraine.” Frontiers in pediatrics (2025). PMID: 40677285 ↗
L2COHORTCited in: Severity Grading, Staging & Risk Stratification - [125]
Charlesworth JEG, Navarajasegaran J, Kavirayani A et al.. “Vitamin D may influence disease course in PIMS-TS/MIS-C: An observational cohort study.” Pediatrics international : official journal of the Japan Pediatric Society (2025). PMID: 41099225 ↗
L2COHORTCited in: Severity Grading, Staging & Risk Stratification - [126]
Filippatos F, Kakleas K, Michos A. “Immunopathogenesis and Cytokine Pathways in Reactive Infectious Mucocutaneous Eruption (RIME) in Pediatric Population: Infectious Triggers and Molecular Insights.” Clinical reviews in allergy & immunology (2026). PMID: 42350880 ↗
L5REVIEW_NARRATIVECited in: Severity Grading, Staging & Risk Stratification - [127]
Portman MA, Dahdah NS, Slee A et al.. “Etanercept With IVIg for Acute Kawasaki Disease: A Randomized Controlled Trial.” Pediatrics (2019). PMID: 31048415 ↗
L1RCTCited in: Acute & Emergency Management: Neonatal Resuscitation & Pediatric Stabilization, Long-term & Definitive Management, History and Evolution of Treatment, Prognosis & Natural History, Special Populations - [128]
Ogata S, Ogihara Y, Honda T et al.. “Corticosteroid pulse combination therapy for refractory Kawasaki disease: a randomized trial.” Pediatrics (2011). PMID: 22144699 ↗
L1RCTCited in: Acute & Emergency Management: Neonatal Resuscitation & Pediatric Stabilization, Long-term & Definitive Management, History and Evolution of Treatment - [129]
Newburger JW, Sleeper LA, McCrindle BW et al.. “Randomized trial of pulsed corticosteroid therapy for primary treatment of Kawasaki disease.” The New England journal of medicine (2007). PMID: 17301297 ↗
L1RCTCited in: Acute & Emergency Management: Neonatal Resuscitation & Pediatric Stabilization, Long-term & Definitive Management, History and Evolution of Treatment, Special Populations - [130]
Tremoulet AH, Jain S, Jaggi P et al.. “Infliximab for intensification of primary therapy for Kawasaki disease: a phase 3 randomised, double-blind, placebo-controlled trial.” Lancet (London, England) (2014). PMID: 24572997 ↗
L1RCTCited in: Acute & Emergency Management: Neonatal Resuscitation & Pediatric Stabilization, Long-term & Definitive Management, History and Evolution of Treatment, Prognosis & Natural History, Special Populations - [131]
Burns JC, Best BM, Mejias A et al.. “Infliximab treatment of intravenous immunoglobulin-resistant Kawasaki disease.” The Journal of pediatrics (2008). PMID: 18672254 ↗
L1RCTCited in: Acute & Emergency Management: Neonatal Resuscitation & Pediatric Stabilization, Long-term & Definitive Management, History and Evolution of Treatment, Prognosis & Natural History - [132]
Tremoulet AH, Jain S, Jone PN et al.. “Phase I/IIa Trial of Atorvastatin in Patients with Acute Kawasaki Disease with Coronary Artery Aneurysm.” The Journal of pediatrics (2019). PMID: 31561960 ↗
L2RCTCited in: Acute & Emergency Management: Neonatal Resuscitation & Pediatric Stabilization, Long-term & Definitive Management, History and Evolution of Treatment - [133]
Inoue Y, Okada Y, Shinohara M et al.. “A multicenter prospective randomized trial of corticosteroids in primary therapy for Kawasaki disease: clinical course and coronary artery outcome.” The Journal of pediatrics (2006). PMID: 16939743 ↗
L1RCTCited in: Acute & Emergency Management: Neonatal Resuscitation & Pediatric Stabilization, Long-term & Definitive Management - [134]
Son MB, Gauvreau K, Burns JC et al.. “Infliximab for intravenous immunoglobulin resistance in Kawasaki disease: a retrospective study.” The Journal of pediatrics (2010). PMID: 21129756 ↗
L3RCTCited in: Acute & Emergency Management: Neonatal Resuscitation & Pediatric Stabilization, Long-term & Definitive Management - [135]
Marchesi A, Rigante D, Cimaz R et al.. “Revised recommendations of the Italian Society of Pediatrics about the general management of Kawasaki disease.” Italian journal of pediatrics (2021). PMID: 33494789 ↗
L1GUIDELINECited in: Acute & Emergency Management: Neonatal Resuscitation & Pediatric Stabilization, Long-term & Definitive Management - [136]
Kuo HC, Lin MC, Kao CC et al.. “Intravenous Immunoglobulin Alone for Coronary Artery Lesion Treatment of Kawasaki Disease: A Randomized Clinical Trial.” JAMA network open (2025). PMID: 40178858 ↗
L1RCTCited in: Acute & Emergency Management: Neonatal Resuscitation & Pediatric Stabilization, Long-term & Definitive Management, History and Evolution of Treatment, Prognosis & Natural History - [137]
Portman MA, Jacobs JP, Newburger JW et al.. “Edoxaban for Thromboembolism Prevention in Pediatric Patients With Cardiac Disease.” Journal of the American College of Cardiology (2022). PMID: 36328157 ↗
L1RCTCited in: Acute & Emergency Management: Neonatal Resuscitation & Pediatric Stabilization, Long-term & Definitive Management - [138]
Wilmot EG, Beltrand J, Guerci B et al.. “Tubeless automated insulin delivery versus multiple daily injections in children and adults with type 1 diabetes with elevated HbA1c (RADIANT): a multicentre, international, parallel-group, open-label, randomised, controlled trial.” The lancet. Diabetes & endocrinology (2026). PMID: 41747751 ↗
L1RCTCited in: Acute & Emergency Management: Neonatal Resuscitation & Pediatric Stabilization, Long-term & Definitive Management, History and Evolution of Treatment, Prognosis & Natural History, Special Populations - [139]
Kuniyoshi Y, Tsujimoto Y, Banno M et al.. “Prediction Models for Intravenous Immunoglobulin Resistance in Kawasaki Disease: A Meta-analysis.” Pediatrics (2023). PMID: 37092277 ↗
L2SR_OBSCited in: Long-term & Definitive Management - [140]
Chen S, Dong Y, Kiuchi MG et al.. “Coronary Artery Complication in Kawasaki Disease and the Importance of Early Intervention : A Systematic Review and Meta-analysis.” JAMA pediatrics (2016). PMID: 27749951 ↗
L1SR_OBSCited in: Long-term & Definitive Management, Complications, Special Populations, Prevention, Screening & Surveillance - [141]
Kabbaha S, Milano A, Aldeyab MA et al.. “Infliximab as a second-line therapy for children with refractory Kawasaki disease: A systematic review and meta-analysis of randomized controlled trials.” British journal of clinical pharmacology (2022). PMID: 36169097 ↗
L1SR_MA_RCTCited in: Long-term & Definitive Management - [142]
Lei WT, Chang LS, Zeng BY et al.. “Pharmacologic interventions for Kawasaki disease in children: A network meta-analysis of 56 randomized controlled trials.” EBioMedicine (2022). PMID: 35306339 ↗
L1SR_MA_RCTCited in: Long-term & Definitive Management - [143]
Fukui S, Seki M, Minami T et al.. “Efficacy and safety associated with the infusion speed of intravenous immunoglobulin for the treatment of Kawasaki disease: a randomized controlled trial.” Pediatric rheumatology online journal (2021). PMID: 34217297 ↗
L1RCTCited in: Long-term & Definitive Management - [144]
Newburger JW, Takahashi M, Gerber MA et al.. “Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association.” Pediatrics (2004). PMID: 15574639 ↗
L1GUIDELINECited in: History and Evolution of Treatment - [145]
Dajani A, Taubert K, Ferrieri P et al.. “Treatment of acute streptococcal pharyngitis and prevention of rheumatic fever: a statement for health professionals. Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease of the Council on Cardiovascular Disease in the Young, the American Heart Association.” Pediatrics (1995). PMID: 7567345 ↗
L1GUIDELINECited in: History and Evolution of Treatment - [146]
Brogan PA, Bose A, Burgner D et al.. “Kawasaki disease: an evidence based approach to diagnosis, treatment, and proposals for future research.” Archives of disease in childhood (2002). PMID: 11919108 ↗
L5GUIDELINECited in: History and Evolution of Treatment - [147]
Newburger JW, Takahashi M, Beiser AS et al.. “A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome.” The New England journal of medicine (1991). PMID: 1709446 ↗
L1RCTCited in: History and Evolution of Treatment - [148]
Burns JC, Kushner HI, Bastian JF et al.. “Kawasaki disease: A brief history.” Pediatrics (2000). PMID: 10920183 ↗
L5CASE_REPORTCited in: History and Evolution of Treatment - [149]
Furusho K, Kamiya T, Nakano H et al.. “High-dose intravenous gammaglobulin for Kawasaki disease.” Lancet (London, England) (1984). PMID: 6209513 ↗
L1RCTCited in: History and Evolution of Treatment - [150]
Nagashima M, Matsushima M, Matsuoka H et al.. “High-dose gammaglobulin therapy for Kawasaki disease.” The Journal of pediatrics (1987). PMID: 2437278 ↗
L1RCTCited in: History and Evolution of Treatment - [151]
Sundel RP, Baker AL, Fulton DR et al.. “Corticosteroids in the initial treatment of Kawasaki disease: report of a randomized trial.” The Journal of pediatrics (2003). PMID: 12838187 ↗
L1RCTCited in: History and Evolution of Treatment - [152]
Kume E, Yamakawa M, Miyakoshi C et al.. “Molecular Autopsy With Banked Cord Blood Reveals Brugada Syndrome in Past Sudden Death Case.” Pediatrics (2024). PMID: 38721668 ↗
L4CASE_REPORTCited in: History and Evolution of Treatment - [153]
Jaggi P, Wang W, Dvorchik I et al.. “Patterns of Fever in Children After Primary Treatment for Kawasaki Disease.” The Pediatric infectious disease journal (2015). PMID: 26353031 ↗
L2RCTCited in: History and Evolution of Treatment - [154]
Chiribiri A, Arai AE, DiBella E et al.. “Society for cardiovascular magnetic resonance expert consensus statement on quantitative myocardial perfusion cardiovascular magnetic resonance imaging.” Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance (2025). PMID: 40784605 ↗
L5GUIDELINECited in: History and Evolution of Treatment - [155]
Loughlin J, Mast TC, Doherty MC et al.. “Postmarketing evaluation of the short-term safety of the pentavalent rotavirus vaccine.” The Pediatric infectious disease journal (2012). PMID: 22173146 ↗
L2TRIAL_NONRANDOMCited in: History and Evolution of Treatment - [156]
Cheung YF, Huang GY, Chen SB et al.. “Inflammatory gene polymorphisms and susceptibility to kawasaki disease and its arterial sequelae.” Pediatrics (2008). PMID: 18710885 ↗
L3OTHERCited in: History and Evolution of Treatment, Complications - [157]
Baker AL, Gauvreau K, Newburger JW et al.. “Physical and psychosocial health in children who have had Kawasaki disease.” Pediatrics (2003). PMID: 12612239 ↗
L4OTHERCited in: History and Evolution of Treatment - [158]
Holve TJ, Patel A, Chau Q et al.. “Long-term cardiovascular outcomes in survivors of Kawasaki disease.” Pediatrics (2014). PMID: 24446449 ↗
L2OTHERCited in: History and Evolution of Treatment, Prognosis & Natural History - [159]
Yanagawa H, Yashiro M, Nakamura Y et al.. “Epidemiologic pictures of Kawasaki disease in Japan: from the nationwide incidence survey in 1991 and 1992.” Pediatrics (1995). PMID: 7700743 ↗
L2OTHERCited in: History and Evolution of Treatment - [160]
Hayashi H, Uda K, Araki Y et al.. “Association of Yersinia Infection With Kawasaki Disease: A Prospective Multicenter Cohort Study.” The Pediatric infectious disease journal (2023). PMID: 37725804 ↗
L2COHORTCited in: History and Evolution of Treatment - [161]
Ma X, Wei Z, Niu W et al.. “Meta-analysis: Lipids, vascular function, cardio-cerebrovascular events after previous Kawasaki disease in children.” Journal of clinical lipidology (2025). PMID: 41494937 ↗
L2SR_OBSCited in: History and Evolution of Treatment, Prognosis & Natural History - [162]
Rowley AH, Gonzalez-Crussi F, Gidding SS et al.. “Incomplete Kawasaki disease with coronary artery involvement.” The Journal of pediatrics (1987). PMID: 3819942 ↗
L4CASE_REPORTCited in: History and Evolution of Treatment - [163]
Foster BJ, Bernard C, Drummond KN. “Kawasaki disease complicated by renal artery stenosis.” Archives of disease in childhood (2000). PMID: 10952649 ↗
L4CASE_REPORTCited in: History and Evolution of Treatment - [164]
Charisopoulou D, Iliopoulou S, Kagiet SA et al.. “Subclinical Myocardial Dysfunction Post Kawasaki Disease: A Systematic Review and Meta-Analysis.” Diseases (Basel, Switzerland) (2026). PMID: 42346281 ↗
L2SR_OBSCited in: History and Evolution of Treatment - [165]
Kato H, Inoue O, Kawasaki T et al.. “Adult coronary artery disease probably due to childhood Kawasaki disease.” Lancet (London, England) (1992). PMID: 1359212 ↗
L4OTHERCited in: History and Evolution of Treatment - [166]
Song S, Chen L, Zhou Y et al.. “CD14+ monocytes: the immune communication hub in early vasculitis symptoms of Kawasaki disease.” Frontiers in immunology (2025). PMID: 40207219 ↗
L4TRIAL_NONRANDOMCited in: History and Evolution of Treatment, Growth, Development & Nutrition Impact - [167]
Gupta-Malhotra M, Gruber D, Abraham SS et al.. “Atherosclerosis in survivors of Kawasaki disease.” The Journal of pediatrics (2009). PMID: 19595365 ↗
L3OTHERCited in: History and Evolution of Treatment - [168]
Lin J, Jain S, Sun X et al.. “Lipoprotein particle concentrations in children and adults following Kawasaki disease.” The Journal of pediatrics (2014). PMID: 25039043 ↗
L3OTHERCited in: History and Evolution of Treatment - [169]
Elias MD, Brothers JA, Hogarty AN et al.. “Outcomes Associated with Giant Coronary Artery Aneurysms after Kawasaki Disease: A Single-Center United States Experience.” The Journal of pediatrics (2024). PMID: 38878963 ↗
L2OTHERCited in: History and Evolution of Treatment, Complications, Prevention, Screening & Surveillance - [170]
Lee YS, Quek SC, Koay ES et al.. “Chikungunya mimicking atypical Kawasaki disease in an infant.” The Pediatric infectious disease journal (2010). PMID: 19935121 ↗
L4CASE_REPORTCited in: History and Evolution of Treatment - [171]
Zhu Y, Zhou Z, Hu L et al.. “Clinical impact of multimodal cardiac imaging in Kawasaki disease: a prospective Kawasaki disease cardiac imaging (KDCI) cohort study with follow-up data in a Chinese population.” BMJ open (2025). PMID: 41320211 ↗
L2COHORTCited in: History and Evolution of Treatment, Special Populations - [172]
De Rose DU, Campi F, Maddaloni C et al.. “Off-Label Use of Anakinra in Inflammatory Conditions in Neonates and Infants Up to 3 Months of Age: A Case Series and a Review of the Literature.” Paediatric drugs (2025). PMID: 39804459 ↗
L4CASE_REPORTCited in: History and Evolution of Treatment - [173]
Hayashida K, Ae R, Masuda H et al.. “Clinical Characteristics of Patients With Kawasaki Disease Whose Siblings Had the Same Disease.” The Pediatric infectious disease journal (2021). PMID: 33902073 ↗
L2OTHERCited in: History and Evolution of Treatment, Growth, Development & Nutrition Impact - [174]
Phamduy TT, Smith S, Herbst KW et al.. “Kawasaki Disease Hospitalizations in the United States 2016-2020: A Comparison of Before and During the Coronavirus Disease 2019 Era.” The Pediatric infectious disease journal (2021). PMID: 34382611 ↗
L2OTHERCited in: History and Evolution of Treatment, Complications - [175]
Uehara R, Igarashi H, Yashiro M et al.. “Kawasaki disease patients with redness or crust formation at the Bacille Calmette-Guérin inoculation site.” The Pediatric infectious disease journal (2010). PMID: 20032807 ↗
L3OTHERCited in: History and Evolution of Treatment, Prevention, Screening & Surveillance - [176]
Chen JJ, Ma XJ, Liu F et al.. “Epidemiologic Features of Kawasaki Disease in Shanghai From 2008 Through 2012.” The Pediatric infectious disease journal (2016). PMID: 26372452 ↗
L4OTHERCited in: History and Evolution of Treatment - [177]
Deng YB, Li TL, Xiang HJ et al.. “Impaired endothelial function in the brachial artery after Kawasaki disease and the effects of intravenous administration of vitamin C.” The Pediatric infectious disease journal (2003). PMID: 12544406 ↗
L4OTHERCited in: History and Evolution of Treatment - [178]
Wu ZC, Pan Y. “Research on gamma globulin unresponsive Kawasaki disease: A review.” World journal of clinical pediatrics (2025). PMID: 41255659 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment - [179]
Noval Rivas M, Arditi M. “Kawasaki Disease Vasculitis: From Diagnosis to New Concepts in Pathophysiology and Therapeutic Approaches.” Annual review of medicine (2025). PMID: 41160750 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment - [180]
Yang ZY, Pan Y. “Recent advances in research on gene polymorphisms in Kawasaki disease.” World journal of clinical pediatrics (2025). PMID: 40881086 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment - [181]
Tsai MH, Huang YC, Yen MH et al.. “Clinical responses of patients with Kawasaki disease to different brands of intravenous immunoglobulin.” The Journal of pediatrics (2006). PMID: 16423595 ↗
L2TRIAL_NONRANDOMCited in: Growth, Development & Nutrition Impact - [182]
Shin JS, Kim SY, Jang MS et al.. “Comparison of Previous Infectious and Allergic Diseases Between Patients with Kawasaki Disease and Propensity Score-matched Controls: A Nationwide Cohort Study.” The Journal of pediatrics (2022). PMID: 36528056 ↗
L3COHORTCited in: Growth, Development & Nutrition Impact - [183]
Yorifuji T, Tsukahara H, Doi H. “Breastfeeding and Risk of Kawasaki Disease: A Nationwide Longitudinal Survey in Japan.” Pediatrics (2016). PMID: 27244853 ↗
L2OTHERCited in: Growth, Development & Nutrition Impact, Prognosis & Natural History - [184]
Kim TH, Shin JS, Kim SY et al.. “Association of Previous Antibiotics Use and Kawasaki Disease: A Cohort Study of 106,908 Patients.” The Pediatric infectious disease journal (2024). PMID: 38534913 ↗
L3COHORTCited in: Growth, Development & Nutrition Impact, Special Populations - [185]
van Stijn D, Korbee JM, Netea SA et al.. “Treatment and Coronary Artery Aneurysm Formation in Kawasaki Disease: A Per-Day Risk Analysis.” The Journal of pediatrics (2021). PMID: 34968497 ↗
L2OTHERCited in: Growth, Development & Nutrition Impact - [186]
Hoshino S, Shibata Y, Matsubayashi J et al.. “Regional Differences in Kawasaki Disease Incidence Reduction Before and After the Onset of the Coronavirus Disease 2019 Pandemic.” The Journal of pediatrics (2022). PMID: 35850239 ↗
L2OTHERCited in: Growth, Development & Nutrition Impact, Prevention, Screening & Surveillance - [187]
Matsuoka R, Furuno K, Nanishi E et al.. “Delayed Development of Coronary Artery Aneurysm in Patients with Kawasaki Disease Who Were Clinically Responsive to Immunoglobulin.” The Journal of pediatrics (2020). PMID: 32810506 ↗
L4OTHERCited in: Growth, Development & Nutrition Impact - [188]
Nomura Y, Arata M, Koriyama C et al.. “A severe form of Kawasaki disease presenting with only fever and cervical lymphadenopathy at admission.” The Journal of pediatrics (2010). PMID: 20097355 ↗
L2OTHERCited in: Growth, Development & Nutrition Impact, Prevention, Screening & Surveillance - [189]
Kronenberger DW, Zimmers TA, Ralston RK et al.. “Circulating Growth Differentiation Factor 15 (GDF15) in Paediatric Disease: A Systematic Review.” Journal of cachexia, sarcopenia and muscle (2025). PMID: 40019842 ↗
L2SR_OBSCited in: Growth, Development & Nutrition Impact, Prognosis & Natural History - [190]
Eleftheriou D, Levin M, Shingadia D et al.. “Management of Kawasaki disease.” Archives of disease in childhood (2013). PMID: 24162006 ↗
L5REVIEW_NARRATIVECited in: Growth, Development & Nutrition Impact, Complications, Prognosis & Natural History, Prevention, Screening & Surveillance - [191]
Senzaki H. “The pathophysiology of coronary artery aneurysms in Kawasaki disease: role of matrix metalloproteinases.” Archives of disease in childhood (2006). PMID: 16990356 ↗
L5REVIEW_NARRATIVECited in: Growth, Development & Nutrition Impact, Complications, Prognosis & Natural History, Prevention, Screening & Surveillance - [192]
Takikawa H, Ae R, Matsubara Y et al.. “Bacille Calmette-Guérin inoculation site changes and cardiac complications in patients with Kawasaki disease.” Archives of disease in childhood (2020). PMID: 33303488 ↗
L2OTHERCited in: Growth, Development & Nutrition Impact, Prognosis & Natural History, Prevention, Screening & Surveillance - [193]
Suzuki T, Michihata N, Yoshikawa T et al.. “Delivery Type and Other Birth Factors Associated With Kawasaki Disease.” The Pediatric infectious disease journal (2025). PMID: 40440681 ↗
L3OTHERCited in: Growth, Development & Nutrition Impact, Prognosis & Natural History, Special Populations - [194]
Iio K, Morikawa Y, Miyata K et al.. “Identifying Kawasaki Disease With a Low Coronary Artery Aneurysm Risk.” The Pediatric infectious disease journal (2023). PMID: 37053581 ↗
L2OTHERCited in: Growth, Development & Nutrition Impact - [195]
Ae R, Abrams JY, Maddox RA et al.. “Platelet Count Variation and Risk for Coronary Artery Abnormalities in Kawasaki Disease.” The Pediatric infectious disease journal (2020). PMID: 31851145 ↗
L2OTHERCited in: Growth, Development & Nutrition Impact - [196]
Gao Y, Peng L, Liu J et al.. “Establishment and validation of a nomogram for predicting intravenous immunoglobulin resistance and coronary artery lesion involvement in Kawasaki disease: a retrospective study.” Clinical rheumatology (2025). PMID: 39808233 ↗
L4COHORTCited in: Growth, Development & Nutrition Impact - [197]
Atici AE, Jena PK, Carvalho TT et al.. “Sirtuin 1 Activation Mitigates Murine Vasculitis Severity by Promoting Mitophagy.” Circulation research (2026). PMID: 42137941 ↗
L5OTHERCited in: Growth, Development & Nutrition Impact - [198]
Ronzoni L, Di Pietro GM, Lombardi A et al.. “Association of blood group B and of rare variants affecting immune system with multisystem inflammatory syndrome in children in an Italian cohort.” Frontiers in immunology (2026). PMID: 42039215 ↗
L4OTHERCited in: Growth, Development & Nutrition Impact - [199]
Narchi H, Skinner A. “Bacillus Calmette-Guérin scar reactivation (BCGitis) in Kawasaki disease: a scoping review.” European journal of pediatrics (2026). PMID: 42020814 ↗
L2REVIEW_NARRATIVECited in: Growth, Development & Nutrition Impact - [200]
Wittkowski H, Carlomagno R, Georgin-Lavialle S et al.. “Juvenile Inflammatory Rheumatism Real-Life Clinical Practice Strategies (JIR-CliPS) network: methodology and the development process.” Orphanet journal of rare diseases (2026). PMID: 41957845 ↗
L5OTHERCited in: Growth, Development & Nutrition Impact - [201]
Rostad CA, Chahroudi A, Mantus G et al.. “Quantitative SARS-CoV-2 Serology in Children With Multisystem Inflammatory Syndrome (MIS-C).” Pediatrics (2020). PMID: 32879033 ↗
L2OTHERCited in: Complications - [202]
Durall AL, Phillips JR, Weisse ME et al.. “Infantile Kawasaki disease and peripheral gangrene.” The Journal of pediatrics (2006). PMID: 16860142 ↗
L4CASE_REPORTCited in: Complications - [203]
Jimenez-Fernandez SG, Tremoulet AH. “Infliximab treatment of pancreatitis complicating acute kawasaki disease.” The Pediatric infectious disease journal (2012). PMID: 22653489 ↗
L4CASE_REPORTCited in: Complications - [204]
Ye M, Shi Q, Liu F et al.. “Outcomes of Total Arterial Coronary Artery Bypass Grafting for Kawasaki Disease in Pediatric Patients: A Single-Center Cohort Study.” The Annals of thoracic surgery (2025). PMID: 40550319 ↗
L3COHORTCited in: Complications - [205]
Mori M, Matsubara T. “Overview of Guidelines for the Medical Treatment of Acute Kawasaki Disease in Japan (2020 Revised Version) and Positioning of Plasma Exchange Therapy in the Acute Phase.” The Pediatric infectious disease journal (2023). PMID: 37200509 ↗
L5REVIEW_NARRATIVECited in: Complications - [206]
Choi HJ, Gwon SH, Son NH et al.. “Neurologic manifestations in Kawasaki disease and their clinical implications: a Korean nationwide pediatric cohort study.” Pediatrics and neonatology (2025). PMID: 41475993 ↗
L3COHORTCited in: Complications - [207]
Zhou J, Ni C, Wang Z et al.. “Activated partial thromboplastin time levels and coronary artery lesions in Kawasaki disease: A retrospective cohort study.” Microvascular research (2025). PMID: 40345320 ↗
L3COHORTCited in: Complications - [208]
Liu Q, Liu J, Kang T et al.. “A triad of hypertension, heart failure, and glomerular injury in subacute Kawasaki disease: a case report and literature review.” Frontiers in cardiovascular medicine (2026). PMID: 42210989 ↗
L4CASE_REPORTCited in: Complications - [209]
Bellicini I, Bainto E, Shimizu C et al.. “Cyclosporine Treatment in Patients with Kawasaki Disease and Coronary Artery Aneurysms or Treatment Resistance.” The Journal of pediatrics (2025). PMID: 39863079 ↗
L3OTHERCited in: Prognosis & Natural History, Special Populations - [210]
Kolahdoozan M, Kabiri F, Biyabanaki A et al.. “Anakinra use in pediatric kawasaki disease: inflammation control, coronary artery outcomes, and safety.” Pediatric rheumatology online journal (2026). PMID: 42046091 ↗
L5SR_OBSCited in: Prognosis & Natural History - [211]
Ong SKA, Raj D, Lee AWX et al.. “Direct oral anticoagulants in children with giant coronary artery aneurysms from Kawasaki disease: a systematic review and meta-analysis.” Frontiers in cardiovascular medicine (2026). PMID: 42039346 ↗
L1SR_OBSCited in: Prognosis & Natural History - [212]
Leon-Jimenez P, Lorenzo-Martin M, Tomatis-Souverbielle C et al.. “Pan-valvulitis in Children With Kawasaki Disease: A Case Report and Review of the Literature.” The Pediatric infectious disease journal (2023). PMID: 38063514 ↗
L4CASE_REPORTCited in: Prognosis & Natural History - [213]
Milman Y, Landau D, Lebel A et al.. “Differential Serum Phosphate Levels in Pediatric Febrile Syndromes and Their Clinical Significance.” The Pediatric infectious disease journal (2024). PMID: 38985998 ↗
L3OTHERCited in: Prognosis & Natural History - [214]
Pinto FF, Laranjo S, Mota Carmo M et al.. “Twelve Years of Kawasaki Disease in Portugal: Epidemiology in Hospitalized Children.” The Pediatric infectious disease journal (2017). PMID: 27918384 ↗
L2OTHERCited in: Prognosis & Natural History - [215]
Manlhiot C, Yeung RS, Clarizia NA et al.. “Kawasaki disease at the extremes of the age spectrum.” Pediatrics (2009). PMID: 19706564 ↗
L3OTHERCited in: Special Populations - [216]
Barrios-Tascón A, Miura M, Domínguez-Rodríguez S et al.. “Ventricular Repolarization Parameters and Coronary Involvement in Kawasaki Disease.” The Journal of pediatrics (2021). PMID: 34004190 ↗
L4OTHERCited in: Special Populations - [217]
Davies S, Sutton N, Blackstock S et al.. “Predicting IVIG resistance in UK Kawasaki disease.” Archives of disease in childhood (2015). PMID: 25670405 ↗
L3OTHERCited in: Special Populations - [218]
Shimizu D, Hoshina T, Kawamura M et al.. “Seasonality in clinical courses of Kawasaki disease.” Archives of disease in childhood (2018). PMID: 30413486 ↗
L3OTHERCited in: Special Populations - [219]
Ljubas D, Šiftar S, Didović D et al.. “Model-based Differentiation Between Kawasaki Disease and MIS-C: The Importance of the Mitral Valve.” The Pediatric infectious disease journal (2026). PMID: 42403251 ↗
L3OTHERCited in: Special Populations - [220]
Ebato T, Ogata S, Ogihara Y et al.. “The Clinical Utility and Safety of a New Strategy for the Treatment of Refractory Kawasaki Disease.” The Journal of pediatrics (2017). PMID: 29173297 ↗
L4TRIAL_NONRANDOMCited in: Prevention, Screening & Surveillance - [221]
Karatzios C, Scuccimarri R, Chédeville G et al.. “Multisystem Inflammatory Syndrome Following SARS-CoV-2 Vaccination in Two Children.” Pediatrics (2022). PMID: 35614536 ↗
L4CASE_REPORTCited in: Prevention, Screening & Surveillance - [222]
Dallaire F, Fortier-Morissette Z, Blais S et al.. “Aspirin Dose and Prevention of Coronary Abnormalities in Kawasaki Disease.” Pediatrics (2017). PMID: 28562282 ↗
L3OTHERCited in: Prevention, Screening & Surveillance - [223]
Payne RM, Burns KM, Glatz AC et al.. “Apixaban for Prevention of Thromboembolism in Pediatric Heart Disease.” Journal of the American College of Cardiology (2023). PMID: 38057072 ↗
L1RCTCited in: Prevention, Screening & Surveillance - [224]
Wu Y, Hu L, Xie X et al.. “Different dose aspirin plus immunoglobulin (DAPI) for prevention of coronary artery abnormalities in Kawasaki disease: Study protocol for a multi-center, prospective, randomized, open-label, blinded end-point, non-inferiority trial.” American heart journal (2024). PMID: 38508571 ↗
L5TRIAL_NONRANDOMCited in: Prevention, Screening & Surveillance - [225]
Harahsheh AS, Portman MA, Khoury M et al.. “Management of Multisystem Inflammatory Syndrome in Children: Decision-Making Regarding a New Condition in the Absence of Clinical Trial Data.” The Canadian journal of cardiology (2022). PMID: 36455760 ↗
L5TRIAL_NONRANDOMCited in: Prevention, Screening & Surveillance - [226]
Tsuda E, Tsujii N, Hayama Y. “Cardiac Events and the Maximum Diameter of Coronary Artery Aneurysms in Kawasaki Disease.” The Journal of pediatrics (2017). PMID: 28662948 ↗
L2OTHERCited in: Prevention, Screening & Surveillance - [227]
Hatano S, Nakao H, Masuda H et al.. “Effect of additional intravenous immunoglobulin for infliximab-refractory Kawasaki disease: a cohort study.” Pediatric rheumatology online journal (2025). PMID: 40361172 ↗
L4COHORTCited in: Prevention, Screening & Surveillance - [228]
Robinson C, Chanchlani R, Gayowsky A et al.. “Cardiovascular outcomes in children with Kawasaki disease: a population-based cohort study.” Pediatric research (2022). PMID: 36380069 ↗
L2COHORTCited in: Prevention, Screening & Surveillance - [229]
Eleftheriou D, Moraes YC, Purvis C et al.. “Multi-centre, randomised, open-label, blinded endpoint assessed, trial of corticosteroids plus intravenous immunoglobulin (IVIG) and aspirin, versus IVIG and aspirin for prevention of coronary artery aneurysms (CAA) in Kawasaki disease (KD): the KD CAA prevention (KD-CAAP) trial protocol.” Trials (2023). PMID: 36703139 ↗
L5TRIAL_NONRANDOMCited in: Prevention, Screening & Surveillance - [230]
Assempoor R, Abroy AS, Azarboo A et al.. “Different antithrombotic strategies to prevent cardiovascular complications in Kawasaki patients: a systematic review and meta-analysis.” BMC pediatrics (2024). PMID: 39548432 ↗
L1SR_OBSCited in: Prevention, Screening & Surveillance - [231]
Jakob A, Whelan J, Kordecki M et al.. “Kawasaki Disease in Germany: A Prospective, Population-based Study Adjusted for Underreporting.” The Pediatric infectious disease journal (2016). PMID: 26465100 ↗
L2OTHERCited in: Prevention, Screening & Surveillance - [232]
Uhlig U, Kostev K, Schuster V et al.. “Impact of rotavirus vaccination in Germany: rotavirus surveillance, hospitalization, side effects and comparison of vaccines.” The Pediatric infectious disease journal (2014). PMID: 24911897 ↗
L2OTHERCited in: Prevention, Screening & Surveillance - [233]
Lee AM, Burns JC, Tremoulet AH. “Safety of Infliximab Following Live Virus Vaccination in Kawasaki Disease Patients.” The Pediatric infectious disease journal (2017). PMID: 27918378 ↗
L4OTHERCited in: Prevention, Screening & Surveillance - [234]
Garrido-García LM, Castillo-Moguel A, Vázquez-Rivera M et al.. “Reaction of the BCG Scar in the Acute Phase of Kawasaki Disease in Mexican Children.” The Pediatric infectious disease journal (2017). PMID: 28498302 ↗
L4OTHERCited in: Prevention, Screening & Surveillance